gabrielaltay commited on
Commit
884d29f
1 Parent(s): 6ac507f
Files changed (7) hide show
  1. README.md +3 -3
  2. annotation_pairs_scores.tsv +101 -0
  3. bigbiohub.py +208 -0
  4. biosses.py +308 -0
  5. languages.json +792 -0
  6. licenses.json +452 -0
  7. licenses.py +327 -0
README.md CHANGED
@@ -1,3 +1,3 @@
1
- ---
2
- license: gpl-3.0
3
- ---
1
+ ---
2
+ license: gpl-3.0
3
+ ---
annotation_pairs_scores.tsv ADDED
@@ -0,0 +1,101 @@
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
+ sentence_id sentence_1 sentence_2 annotator_a annotator_b annotator_c annotator_d annotator_e
2
+ 1 It has recently been shown that Craf is essential for Kras G12D-induced NSCLC. It has recently become evident that Craf is essential for the onset of Kras-driven non-small cell lung cancer. 4 4 4 4 4
3
+ 2 The Bcl-2 inhibitor ABT-737 induces regression of solid tumors and its derivatives are in the early clinical phase as cancer therapeutics; however, it targets Bcl-2, Bcl-XL, and Bcl-w, but not Mcl-1, which induces resistance against apoptotic cell death triggered by ABT-737. Recently, it has been reported that ABT-737 is not cytotoxic to all tumors cells, and that chemoresistance to ABT-737 is dependent on appreciable levels of Mcl-1 expression, the one Bcl-2 family member it does not effectively inhibit. 3 3 3 3 3
4
+ 3 Previous studies demonstrated that the decrease level of 5 hmC in tumors was due to the reduced expression of TET1/2/3 and IDH2 genes or tumor derived IDH1 and IDH2 mutations. In addition, genetic and functional studies suggest that neomorphic IDH mutations contribute to myeloid transformation, at least in part, by inhibiting TET enzymatic function. 2 2 3 2 2
5
+ 4 More recently, IDH mutations and resultant 2-hydroxyglutarate (2HG) production in leukemia cells were reported to induce global DNA hypermethylation through impaired TET2 catalytic function. It has also been recently reported that mutations of the isocitrate dehydrogenase genes IDH1 and IDH2 can lead to the aberrant production of 2-hydroxyglutarate (2-HG), a metabolite that inhibits TET2 enzymatic activity, resulting in a hypermethylated promoter phenotype in acute myeloid leukemia (AML) tumors carrying IDH1/2 mutations. 3 3 4 3 3
6
+ 5 Recent in vitro studies using shRNA-based approaches have suggested a role for TET2 in regulating myeloid differentiation and in regulating stem/progenitor cell proliferation. Two recent studies used RNAi-mediated Tet2 knock-down in vitro to suggest that TET2 depletion led to impaired hematopoietic differentiation and to preferential myeloid commitment. 3 3 4 3 3
7
+ 6 Recently, it was reported that expression of IDH1R132H suppresses TET2 activity and the mutations of IDH1 and IDH2 genes occur in a mutual exclusive manner with that of TET2 gene in AML. This large-scale study showed that IDH1/IDH2 mutations were mutually exclusive with inactivating TET2 mutations, suggesting that the two types of mutations had similar effects and were thus functionally redundant. 3 3 4 3 3
8
+ 7 Recently, it was reported that expression of IDH1R132H suppresses TET2 activity and the mutations of IDH1 and IDH2 genes occur in a mutual exclusive manner with that of TET2 gene in AML the mechanism was clarified by yet another genomic survey, this time involving acute myelogenous leukemia (AML). 1 1 3 2 1
9
+ 8 expression of an activated form of Ras proteins can induce senescence in some primary fibroblasts. When expressed alone in primary cells however, oncogenic Ras induces premature senescence, a putative tumour suppressor mechanism to protect from uncontrolled proliferation. 3 3 3 3 3
10
+ 9 A high percentage of tumor cells that take on immortalized characteristics show telomerase activity and it has been suggested that hTERT expression may be one of the six key events common to cancer. As a serine/threonine protein kinase, AKT functions by phosphorylating key intermediate signaling molecules, leading to increased cell metabolism, cell growth, cell survival, and cell invasiveness—all hallmarks of cancer. 2 1 1 2 1
11
+ 10 n view of the evidence that many tumors occurring in nature arise from the selection of cells with genetic and/or epigenetic changes. The phenomena of neoplastic development and neoplastic transformation, whether they occur in vivo or in vitro, are thought to represent the accumulation of a series of genetic and epigenetic alterations that disrupt the normal processes of cell division and tissue integrity. 3 3 3 3 3
12
+ 11 The phenomena of neoplastic development and neoplastic transformation, whether they occur in vivo or in vitro, are thought to represent the accumulation of a series of genetic and epigenetic alterations that disrupt the normal processes of cell division and tissue integrity. Neoplastic development represents cumulative genetic and epigenetic events leading to the emergence of cells that can attain a tumorigenic phenotype. 3 3 3 3 3
13
+ 12 Tumorigenesis is a multistage process that involves multiple cell types. Previous studies have suggested a number of hallmark functions that need to be acquired for a cancer to generate, helping researchers understand the complexity in tumor progression in a way of logical, scientific manner. 1 1 1 1 1
14
+ 13 Furthermore, transiently expressed exogenous LATS2 is localized to centrosomes. LATS1 and LATS2 have been detected on interphase and mitotic centrosomes 3 3 3 3 3
15
+ 14 Since in S. cerevisiae DBF2 was shown to be associated with anaphase and/or telophase progression, we examined whether the deletion of the kinase would also affect cell cycle progression in N. crassa Taking into consideration the role that DBF2 homologs have been shown to play in cell cycle progression, predominant localization of DBF-2 in N.crassa is expected. 2 2 2 2 2
16
+ 15 Several computational target prediction approaches, such as TargetScan, PicTar, miRanda, PITA, DIANA-microT and RNAhybrid, have been developed to predict target genes. Three programs, PicTar, miRanda, and TargetScan , were used to predict the targets of miR-21. 2 2 3 2 3
17
+ 16 Several lines of evidence suggest that the known principal RB pathway lesions in human tumors act in a mutual exclusive manner. In individual human tumor specimens, these principal components of the pathway—RB-CDK4/6-p16INK4A—are reported to be targeted in a mutually exclusive manner. 3 3 4 3 4
18
+ 17 The Retinoblastoma protein, pRb, was among the first recognized tumor suppressor proteins, and loss or repression of pRb function is thought to play a causative role in most human cancers. Mutation of the retinoblastoma tumor susceptibility gene (RB1) is the rate-limiting step in the genesis of retinoblastoma and over 90% of human tumors exhibit reduced pRB function. 3 3 3 3 3
19
+ 18 For example, loss of, or functional alterations in, the two major tumor suppressor proteins pRB and p53 cause an up-regulation of ribosome biogenesis in cancer tissues. E2F1 stabilizes p53 by inducing the expression of p19(p14)/ARF, an inhibitor of the mdm2 ubiquitin ligase that targets p53 for proteolysis. 2 2 2 2 2
20
+ 19 Recently, miR-126 was identified as a metastasis suppressing miRNA that is downregulated in relapsing breast cancer, leukemia, and cervical cancer. Subsequent reports showed that miR-126 targeted the oncogene IRS-1 (insulin receptor substrate-1) in breast cancer cells and miR-126 was downregulated in cervical cancer. 3 3 3 3 4
21
+ 20 Recently, miR-126 was identified as a metastasis suppressing miRNA that is downregulated in relapsing breast cancer, leukemia, and cervical cancer. MiR-155 is upregulated in several human tumors, such as chronic lymphocytic leukemia, melanoma, head and neck squamous cell carcinoma, clear-cell kidney cancer , hepatocellular carcinoma, lymphoma, thyroid carcinoma], breast cancer, colon cancer, cervical cancer, pancreatic cancer, and lung cancer. 2 2 2 2 2
22
+ 21 Up-regulation of miR-24 has been observed in a number of cancers, including OSCC. In addition, miR-24 is one of the most abundant miRNAs in cervical cancer cells, and is reportedly up-regulated in solid stomach cancers. 3 3 3 3 3
23
+ 22 MiR-223 seems to be a target molecule of TFs regulating granulopoiesis. Feedback loops in which a miRNA-regulated transcription factor regulates the transcription of its cognate miRNA have been described in a number of animals. 1 1 0 2 2
24
+ 23 Furthermore, a very recent study demonstrated the mechanism that specifies myeloid expression of miR-223 and proposed a unique “minicircuitry” comprised of miR-223 and transcription factors, NFI-A and CAAT enhancer-binding protein α (C/EBPα) miR-223 regulates granulopoiesis by a feedback mechanism and is modulated competitively by the transcription factors nuclear factor I/A (NFI-A) and CCAAT/enhancer binding protein-α (C/EBPα). 3 4 4 3 3
25
+ 24 miR-223 regulates granulopoiesis by a feedback mechanism and is modulated competitively by the transcription factors nuclear factor I/A (NFI-A) and CCAAT/enhancer binding protein-α (C/EBPα) There is growing evidence from animal systems that miRNA-regulated transcription factors frequently regulate the transcription of their cognate miRNAs. 1 2 2 2 2
26
+ 25 In myelopoiesis, miR-223 has been shown to regulate granulocyte development in both humans and mice. As shown previously, miR-223 is highly conserved, and its myeloid-specific expression is also well characterized in both human and mouse 3 3 4 4 4
27
+ 26 To clarify the roles of miRNAs in erythropoiesis, four miRNAs were selected (miR-155, miR-221, miR-223, and miR-451) because their expression seems to be relevant to hematopoiesis. In myelopoiesis, miR-223 has been shown to regulate granulocyte development in both humans and mice. 2 2 2 2 2
28
+ 27 We then sought to reassess the regulation of miR-223 in the exactly same experimental system adopted in the previous work Importantly, our reassessment revealed that this conserved promoter is probably active in the induction of miR-223 during All-trans retinoic acid (ATRA)-induced differentiation of the APL cell line, NB4 cells, which is the main experimental system adopted in the previous study 2 3 3 2 2
29
+ 28 Unique segments of homologous sequences in RIP1 and RIP3 (RIP homotypic interaction motifs, RHIMs) were shown to mediate their interaction RIP1 was reported to interact with RIP3. 3 3 4 3 4
30
+ 29 This form of necrosis, also termed necroptosis, requires the activity of receptor-interacting protein kinase 1 (RIP1) and its related kinase, RIP3 TNF-mediated programmed necrosis typically involves the receptor-interacting serine-threonine kinases 1 and 3 (RIP1 and RIP3), as evidenced in human, mouse, and zebrafish cell lines, as well as in a murine sepsis model 3 3 3 3 3
31
+ 30 This form of necrosis, also termed necroptosis, requires the activity of receptor-interacting protein kinase 1 (RIP1) and its related kinase, RIP3 Moreover, other reports have also shown that necroptosis could be induced via modulating RIP1 and RIP3. 4 4 4 4 4
32
+ 31 Furthermore, ablation of both Erk1 and Erk2 impaired tumor development, whereas inactivation of either one alone had no effect. Only concomitant ablation of ERK1 and ERK2 impairs tumor growth. 4 4 4 4 4
33
+ 32 Importantly, the role of ERK phosphorylation in Kras-driven NSCLCs has been recently highlighted by the demonstration that ERK activity is essential for Kras-driven lung tumorigenesis. As mentioned above, high ERK activity is crucial for the development of Kras-driven NSCLCs. 3 3 4 3 4
34
+ 33 Lung tumour formation in mice by oncogenic KRAS requires CRaf, but not BRaf. The oncogenic activity of mutant Kras appears dependent on functional Craf but not on Braf. 4 4 3 3 3
35
+ 34 The oncogenic activity of mutant Kras appears dependent on functional Craf, but not on Braf Notably, c-Raf has recently been found essential for development of K-Ras-driven NSCLCs 3 3 3 3 3
36
+ 35 The oncogenic activity of mutant Kras appears dependent on functional Craf. Oncogenic KRAS mutations are common in cancer. 2 2 2 2 2
37
+ 36 BAF53 and β-actin subunits have been implicated in mammalian SWI/SNF-regulated binding to the chromatin/nuclear matrix. In addition, Arp4-related BAF53 and β-actin are components of the human SWI/SNF complex and could play a role in its signal-regulated binding to the chromatin/nuclear matrix 4 4 4 3 4
38
+ 37 The mammalian Arp, BAF53 (BRG-associated factor), and β-actin were initially found as components of the mammalian SWI/SNF-like BAF chromatin-remodeling complex. In addition, Arp4-related BAF53 and β-actin are components of the human SWI/SNF complex and could play a role in its signal-regulated binding to the chromatin/nuclear matrix 3 3 4 3 4
39
+ 38 All known GEFs reconfigure the nucleotide-binding pocket, often opening it by rearranging the switch regions. A characteristic of GEFs is their strong preference for binding nucleotide-free over nucleotide-loaded GTPases. 2 2 2 2 2
40
+ 39 In eukaryotic cells, small G-proteins are critically regulated by Guanine nucleotide Exchange Factors (GEFs) and GTPase Activating Proteins (GAPs). Eukaryotic small G-proteins are often controlled through the balancing actions of GAPs and GEFs. 4 4 4 4 4
41
+ 40 In a previous study in a mouse model of KRas-dependent pancreatic ductal adenocarcinoma, it was shown that oncogenic KRas induces nucleotide biosynthesis largely through the enhancement of the nonoxidative branch of the PPP. Previous results showed that oncogenic Ras elevates ribonucleotide synthesis largely through the nonoxidative branch of the PPP. 3 3 4 3 3
42
+ 41 Importantly, RNAi knockdown of Gfpt1 reduced overall O-GlcNAcylation and blocked KrasG12DA-mediated tumor growth in vitro and in vivo. GFPT1 is the rate-limiting enzyme in the HBP and it has been identified as an important contributor to Kras-driven pancreatic ductal adenocarcinoma (PDAC) 2 2 2 3 2
43
+ 42 We, and others, have recently described the inducible-Kras*p53+/− (iKras*p53+/−) mouse model of pancreatic cancer, that allows tissue-specific, inducible and reversible expression of mutant Kras in combination with a loss of function allele of the tumor suppressor p53. There is a certain variability in these findings: for instance, metastatic potential has been described by other groups using KC or iKras* mice combined with loss of function allele of p53. 3 3 3 3 3
44
+ 43 The overall accuracy of our gene expression classifier was ~88%, and all T-ALL, TEL-AML1-positive, hyperdiploid and E2A-rearranged cases were correctly classified (i.e., 100% sensitivity) which resembled the data previously reported using other strategies for probe set selection and classifier construction. A gene that warrants further studies is the erythropoietin receptor that is 7.4-fold higher expressed in TEL-AML1-positive cases compared to other precursor B-ALL cases confirming other gene expression classification studies. 2 2 2 2 2
45
+ 44 A gene that warrants further studies is the erythropoietin receptor that is 7.4-fold higher expressed in TEL-AML1-positive cases compared to other precursor B-ALL cases confirming other gene expression classification studies. Another recent gene expression study of large numbers of cases provided support for the hypothesis that distinct leukemias are specified by each of the unique chromosomal abnormalities found in lymphoblastic leukemias. 0 0 0 2 1
46
+ 45 MLL-FKBP and MLL-AF9 transformed cells showed persistent expression of Hox a7 and Hox a9 as well as the Hox cofactor Meis 1. Regardless of the mechanism for transcriptional activation, increasing data suggest that Hox a7, Hox a9, and Meis1 are pivotal targets for MLL fusion protein-mediated transformation. 3 3 4 3 3
47
+ 46 These findings were identical to the pattern of expression seen in human acute lymphoid and myeloid leukemias with MLL rearrangements. These genes are consistently expressed in leukemias with MLL rearrangements. 4 3 4 3 4
48
+ 47 miR-Vec constructs were described before, and Dnd1 open-reading frames were cloned as described into a pCS2-based CMV expression vector to contain a double carboxy-terminal HA tag. The pMSCV-blast-miR plasmids, containing either hsa-miR-376a1 human miRNA or control miRNA (hTR-human telomerase RNA), were constructed as described previously. 1 1 0 2 1
49
+ 48 For Sox11 repression by miR-204, Neuro-2a cells (ATCC) were grown on coverslips in 24-well plates for 24 h and then co-transfected with 500 ng of pCAG-GFP expression plasmid and either 500 ng of scrambled-miRVec or miR-204-miRVec expression plasmid containing the pre-miRNA of miR-204 Co-transfection of miRVec-miR-204 and the Renilla-3′ UTR plasmid was in HEK293T cells with TransIT-LT1 Transfection Reagent (Mirus) 2 2 2 2 1
50
+ 49 Consequently miRNAs have been demonstrated to act either as oncogenes (e.g., miR-155, miR-17−5p and miR-21) or tumor suppressors (e.g., miR-34, miR-15a, miR-16−1 and let-7) The extent to which miRNAs specifically affect metastasis remains unclear, as all the miRNAs reported to affect metastasis also exert potentially confounding influences on primary tumor development, apoptosis, and/or cell proliferation 3 3 3 3 2
51
+ 50 Consequently miRNAs have been demonstrated to act either as oncogenes (e.g., miR-155, miR-17−5p and miR-21) or tumor suppressors (e.g., miR-34, miR-15a, miR-16−1 and let-7) Given the extensive involvement of miRNA in physiology, dysregulation of miRNA expression can be associated with cancer pathobiology including oncogenesis], proliferation, epithelial-mesenchymal transition, metastasis, aberrations in metabolism, and angiogenesis, among others 2 3 3 3 3
52
+ 51 In many tumors, there is either overexpression of so-called oncogenic miRNAs (e.g., miR-155, miR-17−5p and miR-21) or downregulation of tumor suppressor miRNAs (e.g., miR-34, miR-15a, miR-16−1 and let-7) Of note, miR-373 had been previously identified as a potential oncogene (together with miR-372) in testicular germ-cell tumors, although it has been proposed that the prometastatic and the oncogenic properties of this miRNA are due to the regulation of different genes (CD44 and LATS2, respectively) 2 2 1 2 2
53
+ 52 To directly measure the effect of endogenous Dnd1 on the activity of endogenous miR-372 family, we used sensor molecules containing the luciferase gene under the control of either wild-type LATS2-3′UTR or a mutant in the 372 target sites The 3′UTRs of p27 and connexin-43 were PCR amplified from genomic DNA and cloned into pGL3 (Promega) downstream of the luciferase gene; constructs bearing the LATS2 3′UTR were described. 1 2 2 2 2
54
+ 53 These models have facilitated the identification of candidate oncogenes and tumor suppressor genes The development of genome-scale libraries of RNAi reagents has facilitated loss-of-function approaches in mammalian cells that have identified candidate tumor-suppressor genes 3 3 1 3 3
55
+ 54 These cells (herein termed TLM-HMECs) are immortal but do not proliferate in the absence of extracellular matrix (ECM) HMECs expressing hTERT and SV40 LT (TLM-HMECs) were cultured in mammary epithelial growth medium (MEGM, Lonza) 1 2 1 2 1
56
+ 55 Ironically, Rest has recently been described as both a tumor suppressor and an oncogene. REST is a transcription factor that represses neuronal genes in non-neural tissues, and plays a prominent tumor suppressor role in epithelial tissues 3 3 4 2 3
57
+ 56 Further, INPP4B was identified out of a collection of RNAis to give rise to anchorage-independent growth in human mammary epithelial cells (HMEC) On the other hand, RASA4/CAPRI (RAS p21 protein activator 4), a suppressor of epithelial cell transformation, functions as a Ca(2+)-dependent Ras GTPase-activating 0protein (GAP) to inactivate the Ras-MAPK pathway following a stimulus that elevates intracellular calcium 1 1 0 1 0
58
+ 57 Alterations in Oct-4 expression promote differentiation and leads to the specification of ectodermal, endodermal or mesodermal primitive progenitors. Additionally, expression of OCT4 and SOX2 has been shown to affect early differentiation genes such as SOX-17 expression. 2 1 2 2 2
59
+ 58 T47D, MCF-7, Skbr3, HeLa, and Caco-2 cells were transfected by electroporation as described previously. MCF7 or HeLa cells were electroporated as described previously to more than 95% efficiency with pSuper constructs against the various targets, and 72 hr later, protein expression was analyzed by SDS-PAGE and Western blotting. 3 3 3 3 3
60
+ 59 It has been shown, however, that ubiquitination of cyclin D1 can efficiently take place following phosphorylation of another site, or without the apparent requirement for phosphorylation. APC-dependent degradation of cyclin D1 does not require threonine 286 phosphorylation, but the presence of a “cyclin degradation box”, however, as observed in the present study, threonine 286 phosphorylation is essential for proteolytic degradation of cyclin D1 in skin 3 3 3 3 3
61
+ 60 A few studies have reported the control of APC/C by genotoxic stress in mammalian cells, Ionizing radiation was shown to activate the APC/C to degrade cyclin D1, which triggers an immediate p53-independent G1 arrest. In fact, genotoxic stresses such as ionizing radiation have been demonstrated to trigger rapid proteolysis of cyclin D1, leading to p53-independent G1 arrest. 4 4 4 3 4
62
+ 61 As p16INK4a blocks the inactivation of pRb by cyclin-dependent kinases, and Arf blocks the inactivation of p53 by Mdm2-mediated proteolysis, both have the capacity to cause cell cycle arrest. By inducing Arf and Ink4a in primary rodent fibroblasts, oncogenic Ras expression leads to growth arrest and premature senescence. 3 3 2 2 2
63
+ 62 For the analysis of expression at different stages of differentiation, data were obtained for 43 mouse samples in StemBase , originating from 16 studies with Affymetrix MOE430A microarray chips, as used in an Oct4 expression profiling study covering murine ESCs, embryonal carcinoma cell lines, and several early differentiated lineages. We investigated the patterns of expression of the Oct4-associated data set in cells at different stages of differentiation, including embryonic carcinoma, embryonic stem cells, embryoid bodies, and various differentiated cell types, on the basis of transcriptomics data. 4 4 4 3 3
64
+ 63 Besides these 28 OCT4-regulated genes, the Oct4-OETN included 8 more genes of a recently published list of OCT4-correlated transcripts expressed in ESCs. Almost half (37) of the Oct4-OETN genes are known Oct4 companions in ESCs, as their expression is directly regulated by or correlated with Oct4. 2 3 3 3 3
65
+ 64 Expression of an activated form of Ras proteins can induce senescence in some primary fibroblasts. The senescent state has been observed to be inducible in certain cultured cells in response to high level expression of genes such as the activated ras oncogene. 3 4 4 3 4
66
+ 65 Activated Ras will transform established lines, such as NIH3T3 cells, it causes a senescence-like growth arrest in primary cells Moreover, oncogenes such as H-RASV12 provoke a stress response in primary cells that results in an irreversible growth arrest, termed premature senescence. 3 3 3 3 3
67
+ 66 Oct-4-dependent transcriptional networks have been described regulating self-renewal and pluripotency in human and mouse ES and EC cells and in human mesenchymal cells. Co-transfection of miRVec-miR-204 and the Renilla-3′ UTR plasmid was in HEK293T cells with TransIT-LT1 Transfection Reagent (Mirus) 0 0 0 0 0
68
+ 67 This oxidative branch activity is elevated in comparison to many cancer cell lines, where the oxidative branch is typically reduced and accounts for <20% of the carbon flow through PPP. The Downward laboratory went all the way from identifying GATA2 as a novel synthetic lethal gene to validating it using Kras-driven GEM models. 0 0 0 0 0
69
+ 68 Accordingly, expression of mutant K-Ras alone is sufficient to drive malignant progression, whereas elimination of mutant K-Ras from established tumors leads to tumor regression. the results of research represent a very important advance in the long-standing fight to conquer lung cancer. 0 0 0 1 0
70
+ 69 Considerable evidence indicates that cancer cells develop dependencies on normal functions of certain genes that can potentially be exploited to improve therapeutic strategies. In the case of cell response to stress, cyclin D1 can be degraded through its binding to the anaphase-promoting complex and a RXXL sequence located in the NH2-terminal part of the protein. 0 0 0 0 0
71
+ 70 In PC9 cells, loss of GATA6 and/or HOPX did not alter cell growth whereas reduction of GATA2 and EGFR inhibited cell viability as previously reported. It has been shown that the activities of many regulatory factors of checkpoints are lost or arrested during the process of tumorigenesis. 0 0 0 1 0
72
+ 71 A recent study identified the importance of the GATA2 transcriptional network in RAS oncogene-driven NSCLC and suggested effective combinations targeting the proteasome together with IL-1 and Rho-signalling. Alternatively, the anaphase promoting complex (APC) is responsible for the rapid degradation of cyclin D1 in cells irradiated with ionizing radiation. 0 0 0 1 0
73
+ 72 The researchers screened human NSCLC cell lines carrying either wild-type or mutant KRAS with an RNAi library against 7,000 human genes. Recently, it was shown that Gata2 fulfills such role in mutant Kras induced NSCLC. 2 2 2 2 1
74
+ 73 A number of studies have identified unbiased strategies to treat KRAS mutant cancers through RNA interference screens, including inhibition of TAK1, STK33, TBK1, WT1, GATA2, and BCL-XL/MEK. This would also permit the use of inhibitors that target a single normal protein on which in particular the tumor cells depend as the result of a mutation in a defined pathway. 2 1 0 2 2
75
+ 74 Finally, researchers combined available inhibitors selective for two of the pathways regulated by GATA2 to treat mice with Kras-driven NSCLCs. In PC9 cells, loss of GATA6 and/or HOPX did not alter cell growth, whereas reduction of GATA2 and EGFR inhibited cell viability as previously reported. 2 2 2 2 1
76
+ 75 They identified that some genes involved in RHO-related signaling pathways were occupied by GATA2 in KRAS mutant but not wild-type tumor cells. The researchers combined available inhibitors selective for two of the pathways regulated by GATA2 to treat mice with Kras-driven NSCLCs 2 2 2 2 2
77
+ 76 The in vivo data is still preliminary and other potential roadblocks such as drug resistance have not been examined. The GEM model used in this study retains wild-type Tp53, suggesting that the tumors successfully treated with bortezomib and fasudil might not be as aggressive as those in most NSCLC patients 0 0 0 0 0
78
+ 77 In spite of these caveats, the results of research represent a very important advance in the long-standing fight to conquer lung cancer We should consider the data of research as an exciting but early step in the long process of drug discovery. 1 1 0 1 1
79
+ 78 Here, looking for agents that could specifically kill KRAS mutant cells, they found that knockdown of GATA2 was synthetically lethal with KRAS mutation Not surprisingly, GATA2 knockdown in KRAS mutant cells resulted in a striking reduction of active GTP-bound RHO proteins, including the downstream ROCK kinase 2 2 3 2 2
80
+ 79 In lung tumors, TRAF6 levels can become elevated by several mechanisms: GATA2lox/lox Sporadic infection of lung cells with Adeno-Cre virus GATA2 loss induces regression of established tumors 1 1 2 2 1
81
+ 80 GATA2 is also of considerable interest; genetic ablation leads to tumor regression in mouse models of adenocarcinoma of the lung, and whereas this transcription factor may appear to be the least druggable of targets, its role in regulating the proteasome suggested therapeutic approaches that appear very promising The GATA2 transcription factor, which is essential for oncogenic K-ras-dependent lung tumor development, binds to the TRAF6 promoter and enhances its expression. 2 2 2 2 1
82
+ 81 BAF53 and β-actin subunits have been implicated in mammalian SWI/SNF-regulated binding to the chromatin/nuclear matrix. β-actin and actin-related proteins have been found in the various ATP-dependent chromatin remodeling complexes 3 3 3 3 3
83
+ 82 Third, human Wts2 is a phosphorylation target of Aurora-A kinase, and this phosphorylation plays a role in regulating centrosomal localization of hWts2 ( Toji et al., 2004) Similarly to PLK1, Aurora-A activity is required for the enrichment or localisation of multiple centrosomal factors which have roles in maturation, including LATS2 [ 22] and CDK5RAP2/Cnn [ 23] (see [ 10] for a review) 1 1 1 2 1
84
+ 83 Changes in miR-146a and miR-146b expression and/or binding have also been implicated in the metastatic and proliferative response associated with the development of papillary thyroid carcinoma (PTC) and cervical cancer, ovarian cancer, breast cancer and pancreatic cancer and prostate cancer. Additionally, loss of LATS2 stimulated reduplication, an activity comparable to that observed when Cyclin E is overexpressed in the absence of p53 0 0 0 1 0
85
+ 84 We found no obvious effect of LATS2-depletion on the Aurora-A kinase activity when monitored by phosphorylation state of Thr288 on Aurora-A [18] (Fig. S2), suggesting that LATS2 may be a downstream of Aurora-A as mentioned in a previous report [8] Among them, miR-143, miR-145 and miR-34a have been shown to inhibit cell proliferation, and miR-146a and miR-21 to increase cell growth 0 0 0 1 0
86
+ 85 Oct-4-dependent transcriptional networks have been described regulating self-renewal and pluripotency in human and mouse ES and EC cells and in human mesenchymal cells. One study reports upregulation of this miR as revealed by qRT-PCR whereas a sequencing approach and microarray analysis point to a repression of miR-133b in tumor tissue 1 1 0 1 0
87
+ 86 In addition, genetic and functional studies suggest that neomorphic IDH mutations contribute to myeloid transformation, at least in part, by inhibiting TET enzymatic function. In addition, up-regulation of miR-24 has also been observed in gastric and cervical cancers 0 0 0 1 0
88
+ 87 In PC9 cells, loss of GATA6 and/or HOPX did not alter cell growth, whereas reduction of GATA2 and EGFR inhibited cell viability as previously reported. Aurora-A is required for the correct localisation and function of centrosomal components like centrosomin, NDEL1, LATS and TACC proteins 0 0 0 1 0
89
+ 88 Centrosomes increase both in size and in microtubule-nucleating capacity just before mitotic entry. Functional studies showed that, when introduced into cell lines, miR-146a was found to promote cell proliferation in cervical cancer cells, which suggests that miR-146a works as an oncogenic miRNA in these cancers. 0 0 0 0 0
90
+ 89 With respect to LATS2, it has been reported that LATS2 induces G2/M arrest and subsequent apoptotic cell death. The expression of miR-146a has been found to be up-regulated in papillary thyroid carcinoma, anaplastic thyroid cancer and cervical cancer. 0 0 0 1 0
91
+ 90 The up-regulation of miR-146a was also detected in cervical cancer tissues. Similarly to PLK1, Aurora-A activity is required for the enrichment or localisation of multiple centrosomal factors which have roles in maturation, including LATS2 and CDK5RAP2/Cnn. 0 0 0 1 0
92
+ 91 Necroptosis is also part of host defense against virus infection. Necrotic death was augmented when caspase activities were compromised by either viral or chemical inhibitors. 2 2 1 3 2
93
+ 92 Necrotic death was augmented when caspase activities were compromised by either viral or chemical inhibitors. Intriguingly, in the presence of caspase inhibitors or following caspase-8 gene ablation, death receptors have also recently been shown to induce necrotic cell death, a process which is dependent on the kinase activity of RIPK1 and RIPK3 3 3 3 3 2
94
+ 93 The cyclin-dependent kinase (CDK) inhibitor roscovitine has been reported to down-regulate the anti-apoptotic protein Mcl-1 Recent work in model systems and acute myelogenous leukemia has suggested that expression of MCL-1 is a key determinant of resistance to ABT-737 2 2 2 2 2
95
+ 94 The up-regulation of miR-146a was also detected in cervical cancer tissues. The expression of miR-146a has been found to be up-regulated in cervical cancer. 4 4 4 4 4
96
+ 95 At the onset of mitosis, LATS2 is activated by phosphorylation and plays important roles in G2/M transition in cultured cells Lats2/Kpm is homologous to Lats1 and undergoes cell cycle-dependent phosphorylation 3 3 3 3 3
97
+ 96 Ironically, Rest has recently been described as both a tumor suppressor and an oncogene. In human epithelial cells REST has been described as a potent suppressor of malignant transformation and its deregulation has been associated with several non-neural tumors including breast and small cell lung cancers 3 3 3 3 4
98
+ 97 Alterations in Oct-4 expression promote differentiation and leads to the specification of ectodermal, endodermal or mesodermal primitive progenitors. OCT4, a transcript of POU5F1, plays a role in maintaining stem cell pluripotency, self-renewal and chromatin structure in stem cells, and promotes tumor growth in a dose-dependent manner. 1 1 1 3 2
99
+ 98 Three programs, PicTar, miRanda, and TargetScan , were used to predict the targets of miR-21. The genes that decreased 2-fold or more were further screened for possible miR-372/3 target sites using a local version of the TargetScan algorithm. 2 3 2 3 2
100
+ 99 The recent reports demonstrated that the first eight nucleotides of the 5′ end of miRNA could correlate with the efficient translational repression. Mismatches near the 5′ end of the small RNA completely abrogated translational suppression. 3 3 4 3 3
101
+ 100 Oncogenic KRAS mutations are common in cancer. Notably, c-Raf has recently been found essential for development of K-Ras-driven NSCLCs. 2 2 1 2 2
bigbiohub.py ADDED
@@ -0,0 +1,208 @@
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
+ import json
2
+ from collections import defaultdict
3
+ from enum import Enum
4
+ from types import SimpleNamespace
5
+
6
+ from dataclasses import dataclass
7
+ import datasets
8
+
9
+ from . licenses import License, Licenses
10
+
11
+
12
+ BigBioValues = SimpleNamespace(NULL="<BB_NULL_STR>")
13
+
14
+
15
+ @dataclass
16
+ class BigBioConfig(datasets.BuilderConfig):
17
+ """BuilderConfig for BigBio."""
18
+
19
+ name: str = None
20
+ version: datasets.Version = None
21
+ description: str = None
22
+ schema: str = None
23
+ subset_id: str = None
24
+
25
+
26
+ # shamelessly compied from:
27
+ # https://github.com/huggingface/datasets/blob/master/src/datasets/utils/metadata.py
28
+ langs_json = json.load(open("languages.json", "r"))
29
+ langs_dict = {k.replace("-", "_").upper(): v for k, v in langs_json.items()}
30
+ Lang = Enum("Lang", langs_dict)
31
+
32
+
33
+ METADATA: dict = {
34
+ "_LOCAL": bool,
35
+ "_LANGUAGES": Lang,
36
+ "_PUBMED": bool,
37
+ "_LICENSE": License,
38
+ "_DISPLAYNAME": str,
39
+ }
40
+
41
+
42
+ class Tasks(Enum):
43
+ NAMED_ENTITY_RECOGNITION = "NER"
44
+ NAMED_ENTITY_DISAMBIGUATION = "NED"
45
+ EVENT_EXTRACTION = "EE"
46
+ RELATION_EXTRACTION = "RE"
47
+ COREFERENCE_RESOLUTION = "COREF"
48
+ QUESTION_ANSWERING = "QA"
49
+ TEXTUAL_ENTAILMENT = "TE"
50
+ SEMANTIC_SIMILARITY = "STS"
51
+ TEXT_PAIRS_CLASSIFICATION = "TXT2CLASS"
52
+ PARAPHRASING = "PARA"
53
+ TRANSLATION = "TRANSL"
54
+ SUMMARIZATION = "SUM"
55
+ TEXT_CLASSIFICATION = "TXTCLASS"
56
+
57
+
58
+ TASK_TO_SCHEMA = {
59
+ Tasks.NAMED_ENTITY_RECOGNITION: "KB",
60
+ Tasks.NAMED_ENTITY_DISAMBIGUATION: "KB",
61
+ Tasks.EVENT_EXTRACTION: "KB",
62
+ Tasks.RELATION_EXTRACTION: "KB",
63
+ Tasks.COREFERENCE_RESOLUTION: "KB",
64
+ Tasks.QUESTION_ANSWERING: "QA",
65
+ Tasks.TEXTUAL_ENTAILMENT: "TE",
66
+ Tasks.SEMANTIC_SIMILARITY: "PAIRS",
67
+ Tasks.TEXT_PAIRS_CLASSIFICATION: "PAIRS",
68
+ Tasks.PARAPHRASING: "T2T",
69
+ Tasks.TRANSLATION: "T2T",
70
+ Tasks.SUMMARIZATION: "T2T",
71
+ Tasks.TEXT_CLASSIFICATION: "TEXT",
72
+ }
73
+
74
+ SCHEMA_TO_TASKS = defaultdict(set)
75
+ for task, schema in TASK_TO_SCHEMA.items():
76
+ SCHEMA_TO_TASKS[schema].add(task)
77
+ SCHEMA_TO_TASKS = dict(SCHEMA_TO_TASKS)
78
+
79
+ VALID_TASKS = set(TASK_TO_SCHEMA.keys())
80
+ VALID_SCHEMAS = set(TASK_TO_SCHEMA.values())
81
+
82
+
83
+ entailment_features = datasets.Features(
84
+ {
85
+ "id": datasets.Value("string"),
86
+ "premise": datasets.Value("string"),
87
+ "hypothesis": datasets.Value("string"),
88
+ "label": datasets.Value("string"),
89
+ }
90
+ )
91
+
92
+ pairs_features = datasets.Features(
93
+ {
94
+ "id": datasets.Value("string"),
95
+ "document_id": datasets.Value("string"),
96
+ "text_1": datasets.Value("string"),
97
+ "text_2": datasets.Value("string"),
98
+ "label": datasets.Value("string"),
99
+ }
100
+ )
101
+
102
+ qa_features = datasets.Features(
103
+ {
104
+ "id": datasets.Value("string"),
105
+ "question_id": datasets.Value("string"),
106
+ "document_id": datasets.Value("string"),
107
+ "question": datasets.Value("string"),
108
+ "type": datasets.Value("string"),
109
+ "choices": [datasets.Value("string")],
110
+ "context": datasets.Value("string"),
111
+ "answer": datasets.Sequence(datasets.Value("string")),
112
+ }
113
+ )
114
+
115
+ text_features = datasets.Features(
116
+ {
117
+ "id": datasets.Value("string"),
118
+ "document_id": datasets.Value("string"),
119
+ "text": datasets.Value("string"),
120
+ "labels": [datasets.Value("string")],
121
+ }
122
+ )
123
+
124
+ text2text_features = datasets.Features(
125
+ {
126
+ "id": datasets.Value("string"),
127
+ "document_id": datasets.Value("string"),
128
+ "text_1": datasets.Value("string"),
129
+ "text_2": datasets.Value("string"),
130
+ "text_1_name": datasets.Value("string"),
131
+ "text_2_name": datasets.Value("string"),
132
+ }
133
+ )
134
+
135
+ kb_features = datasets.Features(
136
+ {
137
+ "id": datasets.Value("string"),
138
+ "document_id": datasets.Value("string"),
139
+ "passages": [
140
+ {
141
+ "id": datasets.Value("string"),
142
+ "type": datasets.Value("string"),
143
+ "text": datasets.Sequence(datasets.Value("string")),
144
+ "offsets": datasets.Sequence([datasets.Value("int32")]),
145
+ }
146
+ ],
147
+ "entities": [
148
+ {
149
+ "id": datasets.Value("string"),
150
+ "type": datasets.Value("string"),
151
+ "text": datasets.Sequence(datasets.Value("string")),
152
+ "offsets": datasets.Sequence([datasets.Value("int32")]),
153
+ "normalized": [
154
+ {
155
+ "db_name": datasets.Value("string"),
156
+ "db_id": datasets.Value("string"),
157
+ }
158
+ ],
159
+ }
160
+ ],
161
+ "events": [
162
+ {
163
+ "id": datasets.Value("string"),
164
+ "type": datasets.Value("string"),
165
+ # refers to the text_bound_annotation of the trigger
166
+ "trigger": {
167
+ "text": datasets.Sequence(datasets.Value("string")),
168
+ "offsets": datasets.Sequence([datasets.Value("int32")]),
169
+ },
170
+ "arguments": [
171
+ {
172
+ "role": datasets.Value("string"),
173
+ "ref_id": datasets.Value("string"),
174
+ }
175
+ ],
176
+ }
177
+ ],
178
+ "coreferences": [
179
+ {
180
+ "id": datasets.Value("string"),
181
+ "entity_ids": datasets.Sequence(datasets.Value("string")),
182
+ }
183
+ ],
184
+ "relations": [
185
+ {
186
+ "id": datasets.Value("string"),
187
+ "type": datasets.Value("string"),
188
+ "arg1_id": datasets.Value("string"),
189
+ "arg2_id": datasets.Value("string"),
190
+ "normalized": [
191
+ {
192
+ "db_name": datasets.Value("string"),
193
+ "db_id": datasets.Value("string"),
194
+ }
195
+ ],
196
+ }
197
+ ],
198
+ }
199
+ )
200
+
201
+ SCHEMA_TO_FEATURES = {
202
+ "KB": kb_features,
203
+ "QA": qa_features,
204
+ "TE": entailment_features,
205
+ "T2T": text2text_features,
206
+ "TEXT": text_features,
207
+ "PAIRS": pairs_features,
208
+ }
biosses.py ADDED
@@ -0,0 +1,308 @@
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
+ # coding=utf-8
2
+ # Copyright 2020 The HuggingFace Datasets Authors and the current dataset script contributor.
3
+ #
4
+ # Licensed under the Apache License, Version 2.0 (the "License");
5
+ # you may not use this file except in compliance with the License.
6
+ # You may obtain a copy of the License at
7
+ #
8
+ # http://www.apache.org/licenses/LICENSE-2.0
9
+ #
10
+ # Unless required by applicable law or agreed to in writing, software
11
+ # distributed under the License is distributed on an "AS IS" BASIS,
12
+ # WITHOUT WARRANTIES OR CONDITIONS OF ANY KIND, either express or implied.
13
+ # See the License for the specific language governing permissions and
14
+ # limitations under the License.
15
+ """
16
+ BioSSES computes similarity of biomedical sentences by utilizing WordNet as the
17
+ general domain ontology and UMLS as the biomedical domain specific ontology.
18
+ The original paper outlines the approaches with respect to using annotator
19
+ score as golden standard. Source view will return all annotator score
20
+ individually whereas the Bigbio view will return the mean of the annotator
21
+ score.
22
+
23
+ Note: The original files are Word documents, compressed using RAR. This data
24
+ loader uses a version that privides the same data in text format.
25
+ """
26
+ import datasets
27
+ import pandas as pd
28
+
29
+ from bigbiohub import pairs_features
30
+ from bigbiohub import BigBioConfig
31
+ from bigbiohub import Lang, Tasks
32
+ from bigbiohub import Licenses
33
+
34
+ _DATASETNAME = "biosses"
35
+ _DISPLAYNAME = "BIOSSES"
36
+
37
+ _LANGUAGES = [Lang.EN]
38
+ _PUBMED = False
39
+ _LOCAL = False
40
+ _CITATION = """
41
+ @article{souganciouglu2017biosses,
42
+ title={BIOSSES: a semantic sentence similarity estimation system for the biomedical domain},
43
+ author={Soğancıoğlu, Gizem, Hakime Öztürk, and Arzucan Özgür},
44
+ journal={Bioinformatics},
45
+ volume={33},
46
+ number={14},
47
+ pages={i49--i58},
48
+ year={2017},
49
+ publisher={Oxford University Press}
50
+ }
51
+ """
52
+
53
+ _DESCRIPTION = """
54
+ BioSSES computes similarity of biomedical sentences by utilizing WordNet as the
55
+ general domain ontology and UMLS as the biomedical domain specific ontology.
56
+ The original paper outlines the approaches with respect to using annotator
57
+ score as golden standard. Source view will return all annotator score
58
+ individually whereas the Bigbio view will return the mean of the annotator
59
+ score.
60
+ """
61
+
62
+ _HOMEPAGE = "https://tabilab.cmpe.boun.edu.tr/BIOSSES/DataSet.html"
63
+
64
+ _LICENSE = Licenses.GPL_3p0
65
+
66
+ _URLs = {
67
+ "source": "https://huggingface.co/datasets/bigscience-biomedical/biosses/raw/main/annotation_pairs_scores.tsv",
68
+ "bigbio_pairs": "https://huggingface.co/datasets/bigscience-biomedical/biosses/raw/main/annotation_pairs_scores.tsv",
69
+ }
70
+
71
+ _SUPPORTED_TASKS = [Tasks.SEMANTIC_SIMILARITY]
72
+ _SOURCE_VERSION = "1.0.0"
73
+ _BIGBIO_VERSION = "1.0.0"
74
+
75
+
76
+ # The BIOSSES dataset does not provide canonical train/dev/test splits.
77
+ # However the BLUE and BLURB datasets use the following split definitions.
78
+ # see https://github.com/bigscience-workshop/biomedical/issues/664
79
+
80
+ TRAIN_INDEXES = [
81
+ 78,
82
+ 45,
83
+ 35,
84
+ 50,
85
+ 27,
86
+ 13,
87
+ 87,
88
+ 1,
89
+ 58,
90
+ 99,
91
+ 55,
92
+ 74,
93
+ 66,
94
+ 39,
95
+ 44,
96
+ 18,
97
+ 84,
98
+ 76,
99
+ 19,
100
+ 10,
101
+ 75,
102
+ 46,
103
+ 15,
104
+ 86,
105
+ 60,
106
+ 14,
107
+ 51,
108
+ 79,
109
+ 29,
110
+ 34,
111
+ 94,
112
+ 28,
113
+ 62,
114
+ 42,
115
+ 21,
116
+ 30,
117
+ 11,
118
+ 53,
119
+ 6,
120
+ 12,
121
+ 26,
122
+ 48,
123
+ 31,
124
+ 32,
125
+ 77,
126
+ 37,
127
+ 95,
128
+ 85,
129
+ 36,
130
+ 56,
131
+ 43,
132
+ 61,
133
+ 16,
134
+ 5,
135
+ 67,
136
+ 65,
137
+ 54,
138
+ 3,
139
+ 73,
140
+ 98,
141
+ 17,
142
+ 4,
143
+ 92,
144
+ 93,
145
+ ]
146
+ DEV_INDEXES = [
147
+ 88,
148
+ 82,
149
+ 8,
150
+ 63,
151
+ 47,
152
+ 68,
153
+ 40,
154
+ 90,
155
+ 100,
156
+ 24,
157
+ 41,
158
+ 91,
159
+ 80,
160
+ 9,
161
+ 72,
162
+ 2,
163
+ ]
164
+ TEST_INDEXES = [
165
+ 59,
166
+ 96,
167
+ 70,
168
+ 22,
169
+ 81,
170
+ 38,
171
+ 57,
172
+ 23,
173
+ 33,
174
+ 89,
175
+ 69,
176
+ 49,
177
+ 7,
178
+ 71,
179
+ 97,
180
+ 25,
181
+ 83,
182
+ 64,
183
+ 52,
184
+ 20,
185
+ ]
186
+
187
+
188
+ class BiossesDataset(datasets.GeneratorBasedBuilder):
189
+ """BIOSSES : Biomedical Semantic Similarity Estimation System"""
190
+
191
+ DEFAULT_CONFIG_NAME = "biosses_source"
192
+ SOURCE_VERSION = datasets.Version(_SOURCE_VERSION)
193
+ BIGBIO_VERSION = datasets.Version(_BIGBIO_VERSION)
194
+
195
+ BUILDER_CONFIGS = [
196
+ BigBioConfig(
197
+ name="biosses_source",
198
+ version=SOURCE_VERSION,
199
+ description="BIOSSES source schema",
200
+ schema="source",
201
+ subset_id="biosses",
202
+ ),
203
+ BigBioConfig(
204
+ name="biosses_bigbio_pairs",
205
+ version=BIGBIO_VERSION,
206
+ description="BIOSSES simplified BigBio schema",
207
+ schema="bigbio_pairs",
208
+ subset_id="biosses",
209
+ ),
210
+ ]
211
+
212
+ def _info(self):
213
+
214
+ if self.config.name == "biosses_source":
215
+ features = datasets.Features(
216
+ {
217
+ "id": datasets.Value("int64"),
218
+ "document_id": datasets.Value("int64"),
219
+ "text_1": datasets.Value("string"),
220
+ "text_2": datasets.Value("string"),
221
+ "annotator_a": datasets.Value("int64"),
222
+ "annotator_b": datasets.Value("int64"),
223
+ "annotator_c": datasets.Value("int64"),
224
+ "annotator_d": datasets.Value("int64"),
225
+ "annotator_e": datasets.Value("int64"),
226
+ }
227
+ )
228
+ elif self.config.name == "biosses_bigbio_pairs":
229
+ features = pairs_features
230
+
231
+ return datasets.DatasetInfo(
232
+ description=_DESCRIPTION,
233
+ features=features,
234
+ supervised_keys=None,
235
+ homepage=_HOMEPAGE,
236
+ license=str(_LICENSE),
237
+ citation=_CITATION,
238
+ )
239
+
240
+ def _split_generators(self, dl_manager):
241
+
242
+ my_urls = _URLs[self.config.schema]
243
+ dl_dir = dl_manager.download_and_extract(my_urls)
244
+
245
+ return [
246
+ datasets.SplitGenerator(
247
+ name=datasets.Split.TRAIN,
248
+ gen_kwargs={
249
+ "filepath": dl_dir,
250
+ "split": "train",
251
+ "indexes": TRAIN_INDEXES,
252
+ },
253
+ ),
254
+ datasets.SplitGenerator(
255
+ name=datasets.Split.VALIDATION,
256
+ gen_kwargs={
257
+ "filepath": dl_dir,
258
+ "split": "validation",
259
+ "indexes": DEV_INDEXES,
260
+ },
261
+ ),
262
+ datasets.SplitGenerator(
263
+ name=datasets.Split.TEST,
264
+ gen_kwargs={
265
+ "filepath": dl_dir,
266
+ "split": "test",
267
+ "indexes": TEST_INDEXES,
268
+ },
269
+ ),
270
+ ]
271
+
272
+ def _generate_examples(self, filepath, split, indexes):
273
+
274
+ df = pd.read_csv(filepath, sep="\t", encoding="utf-8")
275
+ df = df[df["sentence_id"].isin(indexes)]
276
+
277
+ if self.config.schema == "source":
278
+ for uid, row in df.iterrows():
279
+ yield uid, {
280
+ "id": uid,
281
+ "document_id": row["sentence_id"],
282
+ "text_1": row["sentence_1"],
283
+ "text_2": row["sentence_2"],
284
+ "annotator_a": row["annotator_a"],
285
+ "annotator_b": row["annotator_b"],
286
+ "annotator_c": row["annotator_c"],
287
+ "annotator_d": row["annotator_d"],
288
+ "annotator_e": row["annotator_e"],
289
+ }
290
+
291
+ elif self.config.schema == "bigbio_pairs":
292
+ for uid, row in df.iterrows():
293
+ yield uid, {
294
+ "id": uid,
295
+ "document_id": row["sentence_id"],
296
+ "text_1": row["sentence_1"],
297
+ "text_2": row["sentence_2"],
298
+ "label": str(
299
+ (
300
+ row["annotator_a"]
301
+ + row["annotator_b"]
302
+ + row["annotator_c"]
303
+ + row["annotator_d"]
304
+ + row["annotator_e"]
305
+ )
306
+ / 5
307
+ ),
308
+ }
languages.json ADDED
@@ -0,0 +1,792 @@
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
+ {
2
+ "af": "Afrikaans",
3
+ "af-NA": "Afrikaans (Namibia)",
4
+ "af-ZA": "Afrikaans (South Africa)",
5
+ "agq": "Aghem",
6
+ "agq-CM": "Aghem (Cameroon)",
7
+ "ak": "Akan",
8
+ "ak-GH": "Akan (Ghana)",
9
+ "am": "Amharic",
10
+ "am-ET": "Amharic (Ethiopia)",
11
+ "ar": "Arabic",
12
+ "ar-001": "Arabic (World)",
13
+ "ar-AE": "Arabic (United Arab Emirates)",
14
+ "ar-BH": "Arabic (Bahrain)",
15
+ "ar-DJ": "Arabic (Djibouti)",
16
+ "ar-DZ": "Arabic (Algeria)",
17
+ "ar-EG": "Arabic (Egypt)",
18
+ "ar-EH": "Arabic (Western Sahara)",
19
+ "ar-ER": "Arabic (Eritrea)",
20
+ "ar-IL": "Arabic (Israel)",
21
+ "ar-IQ": "Arabic (Iraq)",
22
+ "ar-JO": "Arabic (Jordan)",
23
+ "ar-KM": "Arabic (Comoros)",
24
+ "ar-KW": "Arabic (Kuwait)",
25
+ "ar-LB": "Arabic (Lebanon)",
26
+ "ar-LY": "Arabic (Libya)",
27
+ "ar-MA": "Arabic (Morocco)",
28
+ "ar-MR": "Arabic (Mauritania)",
29
+ "ar-OM": "Arabic (Oman)",
30
+ "ar-PS": "Arabic (Palestinian Territories)",
31
+ "ar-QA": "Arabic (Qatar)",
32
+ "ar-SA": "Arabic (Saudi Arabia)",
33
+ "ar-SD": "Arabic (Sudan)",
34
+ "ar-SO": "Arabic (Somalia)",
35
+ "ar-SS": "Arabic (South Sudan)",
36
+ "ar-SY": "Arabic (Syria)",
37
+ "ar-TD": "Arabic (Chad)",
38
+ "ar-TN": "Arabic (Tunisia)",
39
+ "ar-YE": "Arabic (Yemen)",
40
+ "as": "Assamese",
41
+ "as-IN": "Assamese (India)",
42
+ "asa": "Asu",
43
+ "asa-TZ": "Asu (Tanzania)",
44
+ "ast": "Asturian",
45
+ "ast-ES": "Asturian (Spain)",
46
+ "az": "Azerbaijani",
47
+ "az-Cyrl": "Azerbaijani (Cyrillic)",
48
+ "az-Cyrl-AZ": "Azerbaijani (Cyrillic, Azerbaijan)",
49
+ "az-Latn": "Azerbaijani (Latin)",
50
+ "az-Latn-AZ": "Azerbaijani (Latin, Azerbaijan)",
51
+ "bas": "Basaa",
52
+ "bas-CM": "Basaa (Cameroon)",
53
+ "be": "Belarusian",
54
+ "be-BY": "Belarusian (Belarus)",
55
+ "bem": "Bemba",
56
+ "bem-ZM": "Bemba (Zambia)",
57
+ "bez": "Bena",
58
+ "bez-TZ": "Bena (Tanzania)",
59
+ "bg": "Bulgarian",
60
+ "bg-BG": "Bulgarian (Bulgaria)",
61
+ "bm": "Bambara",
62
+ "bm-ML": "Bambara (Mali)",
63
+ "bn": "Bangla",
64
+ "bn-BD": "Bangla (Bangladesh)",
65
+ "bn-IN": "Bangla (India)",
66
+ "bo": "Tibetan",
67
+ "bo-CN": "Tibetan (China)",
68
+ "bo-IN": "Tibetan (India)",
69
+ "br": "Breton",
70
+ "br-FR": "Breton (France)",
71
+ "brx": "Bodo",
72
+ "brx-IN": "Bodo (India)",
73
+ "bs": "Bosnian",
74
+ "bs-Cyrl": "Bosnian (Cyrillic)",
75
+ "bs-Cyrl-BA": "Bosnian (Cyrillic, Bosnia & Herzegovina)",
76
+ "bs-Latn": "Bosnian",
77
+ "bs-Latn-BA": "Bosnian (Bosnia & Herzegovina)",
78
+ "ca": "Catalan",
79
+ "ca-AD": "Catalan (Andorra)",
80
+ "ca-ES": "Catalan (Spain)",
81
+ "ca-ES-valencia": "Catalan (Spain)",
82
+ "ca-FR": "Catalan (France)",
83
+ "ca-IT": "Catalan (Italy)",
84
+ "ccp": "Chakma",
85
+ "ccp-BD": "Chakma (Bangladesh)",
86
+ "ccp-IN": "Chakma (India)",
87
+ "ce": "Chechen",
88
+ "ce-RU": "Chechen (Russia)",
89
+ "ceb": "Cebuano",
90
+ "ceb-PH": "Cebuano (Philippines)",
91
+ "cgg": "Chiga",
92
+ "cgg-UG": "Chiga (Uganda)",
93
+ "chr": "Cherokee",
94
+ "chr-US": "Cherokee (United States)",
95
+ "ckb": "Central Kurdish",
96
+ "ckb-IQ": "Central Kurdish (Iraq)",
97
+ "ckb-IR": "Central Kurdish (Iran)",
98
+ "cs": "Czech",
99
+ "cs-CZ": "Czech (Czechia)",
100
+ "cu": "Church Slavic",
101
+ "cu-RU": "Church Slavic (Russia)",
102
+ "cy": "Welsh",
103
+ "cy-GB": "Welsh (United Kingdom)",
104
+ "da": "Danish",
105
+ "da-DK": "Danish (Denmark)",
106
+ "da-GL": "Danish (Greenland)",
107
+ "dav": "Taita",
108
+ "dav-KE": "Taita (Kenya)",
109
+ "de": "German",
110
+ "de-AT": "German (Austria)",
111
+ "de-BE": "German (Belgium)",
112
+ "de-CH": "German (Switzerland)",
113
+ "de-DE": "German (Germany)",
114
+ "de-IT": "German (Italy)",
115
+ "de-LI": "German (Liechtenstein)",
116
+ "de-LU": "German (Luxembourg)",
117
+ "dje": "Zarma",
118
+ "dje-NE": "Zarma (Niger)",
119
+ "dsb": "Lower Sorbian",
120
+ "dsb-DE": "Lower Sorbian (Germany)",
121
+ "dua": "Duala",
122
+ "dua-CM": "Duala (Cameroon)",
123
+ "dyo": "Jola-Fonyi",
124
+ "dyo-SN": "Jola-Fonyi (Senegal)",
125
+ "dz": "Dzongkha",
126
+ "dz-BT": "Dzongkha (Bhutan)",
127
+ "ebu": "Embu",
128
+ "ebu-KE": "Embu (Kenya)",
129
+ "ee": "Ewe",
130
+ "ee-GH": "Ewe (Ghana)",
131
+ "ee-TG": "Ewe (Togo)",
132
+ "el": "Greek",
133
+ "el-CY": "Greek (Cyprus)",
134
+ "el-GR": "Greek (Greece)",
135
+ "en": "English",
136
+ "en-001": "English (World)",
137
+ "en-150": "English (Europe)",
138
+ "en-AE": "English (United Arab Emirates)",
139
+ "en-AG": "English (Antigua & Barbuda)",
140
+ "en-AI": "English (Anguilla)",
141
+ "en-AS": "English (American Samoa)",
142
+ "en-AT": "English (Austria)",
143
+ "en-AU": "English (Australia)",
144
+ "en-BB": "English (Barbados)",
145
+ "en-BE": "English (Belgium)",
146
+ "en-BI": "English (Burundi)",
147
+ "en-BM": "English (Bermuda)",
148
+ "en-BS": "English (Bahamas)",
149
+ "en-BW": "English (Botswana)",
150
+ "en-BZ": "English (Belize)",
151
+ "en-CA": "English (Canada)",
152
+ "en-CC": "English (Cocos (Keeling) Islands)",
153
+ "en-CH": "English (Switzerland)",
154
+ "en-CK": "English (Cook Islands)",
155
+ "en-CM": "English (Cameroon)",
156
+ "en-CX": "English (Christmas Island)",
157
+ "en-CY": "English (Cyprus)",
158
+ "en-DE": "English (Germany)",
159
+ "en-DG": "English (Diego Garcia)",
160
+ "en-DK": "English (Denmark)",
161
+ "en-DM": "English (Dominica)",
162
+ "en-ER": "English (Eritrea)",
163
+ "en-FI": "English (Finland)",
164
+ "en-FJ": "English (Fiji)",
165
+ "en-FK": "English (Falkland Islands)",
166
+ "en-FM": "English (Micronesia)",
167
+ "en-GB": "English (United Kingdom)",
168
+ "en-GD": "English (Grenada)",
169
+ "en-GG": "English (Guernsey)",
170
+ "en-GH": "English (Ghana)",
171
+ "en-GI": "English (Gibraltar)",
172
+ "en-GM": "English (Gambia)",
173
+ "en-GU": "English (Guam)",
174
+ "en-GY": "English (Guyana)",
175
+ "en-HK": "English (Hong Kong SAR China)",
176
+ "en-IE": "English (Ireland)",
177
+ "en-IL": "English (Israel)",
178
+ "en-IM": "English (Isle of Man)",
179
+ "en-IN": "English (India)",
180
+ "en-IO": "English (British Indian Ocean Territory)",
181
+ "en-JE": "English (Jersey)",
182
+ "en-JM": "English (Jamaica)",
183
+ "en-KE": "English (Kenya)",
184
+ "en-KI": "English (Kiribati)",
185
+ "en-KN": "English (St. Kitts & Nevis)",
186
+ "en-KY": "English (Cayman Islands)",
187
+ "en-LC": "English (St. Lucia)",
188
+ "en-LR": "English (Liberia)",
189
+ "en-LS": "English (Lesotho)",
190
+ "en-MG": "English (Madagascar)",
191
+ "en-MH": "English (Marshall Islands)",
192
+ "en-MO": "English (Macao SAR China)",
193
+ "en-MP": "English (Northern Mariana Islands)",
194
+ "en-MS": "English (Montserrat)",
195
+ "en-MT": "English (Malta)",
196
+ "en-MU": "English (Mauritius)",
197
+ "en-MW": "English (Malawi)",
198
+ "en-MY": "English (Malaysia)",
199
+ "en-NA": "English (Namibia)",
200
+ "en-NF": "English (Norfolk Island)",
201
+ "en-NG": "English (Nigeria)",
202
+ "en-NL": "English (Netherlands)",
203
+ "en-NR": "English (Nauru)",
204
+ "en-NU": "English (Niue)",
205
+ "en-NZ": "English (New Zealand)",
206
+ "en-PG": "English (Papua New Guinea)",
207
+ "en-PH": "English (Philippines)",
208
+ "en-PK": "English (Pakistan)",
209
+ "en-PN": "English (Pitcairn Islands)",
210
+ "en-PR": "English (Puerto Rico)",
211
+ "en-PW": "English (Palau)",
212
+ "en-RW": "English (Rwanda)",
213
+ "en-SB": "English (Solomon Islands)",
214
+ "en-SC": "English (Seychelles)",
215
+ "en-SD": "English (Sudan)",
216
+ "en-SE": "English (Sweden)",
217
+ "en-SG": "English (Singapore)",
218
+ "en-SH": "English (St. Helena)",
219
+ "en-SI": "English (Slovenia)",
220
+ "en-SL": "English (Sierra Leone)",
221
+ "en-SS": "English (South Sudan)",
222
+ "en-SX": "English (Sint Maarten)",
223
+ "en-SZ": "English (Eswatini)",
224
+ "en-TC": "English (Turks & Caicos Islands)",
225
+ "en-TK": "English (Tokelau)",
226
+ "en-TO": "English (Tonga)",
227
+ "en-TT": "English (Trinidad & Tobago)",
228
+ "en-TV": "English (Tuvalu)",
229
+ "en-TZ": "English (Tanzania)",
230
+ "en-UG": "English (Uganda)",
231
+ "en-UM": "English (U.S. Outlying Islands)",
232
+ "en-US": "English (United States)",
233
+ "en-US-posix": "English (United States)",
234
+ "en-VC": "English (St. Vincent & Grenadines)",
235
+ "en-VG": "English (British Virgin Islands)",
236
+ "en-VI": "English (U.S. Virgin Islands)",
237
+ "en-VU": "English (Vanuatu)",
238
+ "en-WS": "English (Samoa)",
239
+ "en-ZA": "English (South Africa)",
240
+ "en-ZM": "English (Zambia)",
241
+ "en-ZW": "English (Zimbabwe)",
242
+ "eo": "Esperanto",
243
+ "eo-001": "Esperanto (World)",
244
+ "es": "Spanish",
245
+ "es-419": "Spanish (Latin America)",
246
+ "es-AR": "Spanish (Argentina)",
247
+ "es-BO": "Spanish (Bolivia)",
248
+ "es-BR": "Spanish (Brazil)",
249
+ "es-BZ": "Spanish (Belize)",
250
+ "es-CL": "Spanish (Chile)",
251
+ "es-CO": "Spanish (Colombia)",
252
+ "es-CR": "Spanish (Costa Rica)",
253
+ "es-CU": "Spanish (Cuba)",
254
+ "es-DO": "Spanish (Dominican Republic)",
255
+ "es-EA": "Spanish (Ceuta & Melilla)",
256
+ "es-EC": "Spanish (Ecuador)",
257
+ "es-ES": "Spanish (Spain)",
258
+ "es-GQ": "Spanish (Equatorial Guinea)",
259
+ "es-GT": "Spanish (Guatemala)",
260
+ "es-HN": "Spanish (Honduras)",
261
+ "es-IC": "Spanish (Canary Islands)",
262
+ "es-MX": "Spanish (Mexico)",
263
+ "es-NI": "Spanish (Nicaragua)",
264
+ "es-PA": "Spanish (Panama)",
265
+ "es-PE": "Spanish (Peru)",
266
+ "es-PH": "Spanish (Philippines)",
267
+ "es-PR": "Spanish (Puerto Rico)",
268
+ "es-PY": "Spanish (Paraguay)",
269
+ "es-SV": "Spanish (El Salvador)",
270
+ "es-US": "Spanish (United States)",
271
+ "es-UY": "Spanish (Uruguay)",
272
+ "es-VE": "Spanish (Venezuela)",
273
+ "et": "Estonian",
274
+ "et-EE": "Estonian (Estonia)",
275
+ "eu": "Basque",
276
+ "eu-ES": "Basque (Spain)",
277
+ "ewo": "Ewondo",
278
+ "ewo-CM": "Ewondo (Cameroon)",
279
+ "fa": "Persian",
280
+ "fa-AF": "Persian (Afghanistan)",
281
+ "fa-IR": "Persian (Iran)",
282
+ "ff": "Fulah",
283
+ "ff-Adlm": "Fulah (Adlam)",
284
+ "ff-Adlm-BF": "Fulah (Adlam, Burkina Faso)",
285
+ "ff-Adlm-CM": "Fulah (Adlam, Cameroon)",
286
+ "ff-Adlm-GH": "Fulah (Adlam, Ghana)",
287
+ "ff-Adlm-GM": "Fulah (Adlam, Gambia)",
288
+ "ff-Adlm-GN": "Fulah (Adlam, Guinea)",
289
+ "ff-Adlm-GW": "Fulah (Adlam, Guinea-Bissau)",
290
+ "ff-Adlm-LR": "Fulah (Adlam, Liberia)",
291
+ "ff-Adlm-MR": "Fulah (Adlam, Mauritania)",
292
+ "ff-Adlm-NE": "Fulah (Adlam, Niger)",
293
+ "ff-Adlm-NG": "Fulah (Adlam, Nigeria)",
294
+ "ff-Adlm-SL": "Fulah (Adlam, Sierra Leone)",
295
+ "ff-Adlm-SN": "Fulah (Adlam, Senegal)",
296
+ "ff-Latn": "Fulah (Latin)",
297
+ "ff-Latn-BF": "Fulah (Latin, Burkina Faso)",
298
+ "ff-Latn-CM": "Fulah (Latin, Cameroon)",
299
+ "ff-Latn-GH": "Fulah (Latin, Ghana)",
300
+ "ff-Latn-GM": "Fulah (Latin, Gambia)",
301
+ "ff-Latn-GN": "Fulah (Latin, Guinea)",
302
+ "ff-Latn-GW": "Fulah (Latin, Guinea-Bissau)",
303
+ "ff-Latn-LR": "Fulah (Latin, Liberia)",
304
+ "ff-Latn-MR": "Fulah (Latin, Mauritania)",
305
+ "ff-Latn-NE": "Fulah (Latin, Niger)",
306
+ "ff-Latn-NG": "Fulah (Latin, Nigeria)",
307
+ "ff-Latn-SL": "Fulah (Latin, Sierra Leone)",
308
+ "ff-Latn-SN": "Fulah (Latin, Senegal)",
309
+ "fi": "Finnish",
310
+ "fi-FI": "Finnish (Finland)",
311
+ "fil": "Filipino",
312
+ "fil-PH": "Filipino (Philippines)",
313
+ "fo": "Faroese",
314
+ "fo-DK": "Faroese (Denmark)",
315
+ "fo-FO": "Faroese (Faroe Islands)",
316
+ "fr": "French",
317
+ "fr-BE": "French (Belgium)",
318
+ "fr-BF": "French (Burkina Faso)",
319
+ "fr-BI": "French (Burundi)",
320
+ "fr-BJ": "French (Benin)",
321
+ "fr-BL": "French (St. Barth\u00e9lemy)",
322
+ "fr-CA": "French (Canada)",
323
+ "fr-CD": "French (Congo - Kinshasa)",
324
+ "fr-CF": "French (Central African Republic)",
325
+ "fr-CG": "French (Congo - Brazzaville)",
326
+ "fr-CH": "French (Switzerland)",
327
+ "fr-CI": "French (C\u00f4te d\u2019Ivoire)",
328
+ "fr-CM": "French (Cameroon)",
329
+ "fr-DJ": "French (Djibouti)",
330
+ "fr-DZ": "French (Algeria)",
331
+ "fr-FR": "French (France)",
332
+ "fr-GA": "French (Gabon)",
333
+ "fr-GF": "French (French Guiana)",
334
+ "fr-GN": "French (Guinea)",
335
+ "fr-GP": "French (Guadeloupe)",
336
+ "fr-GQ": "French (Equatorial Guinea)",
337
+ "fr-HT": "French (Haiti)",
338
+ "fr-KM": "French (Comoros)",
339
+ "fr-LU": "French (Luxembourg)",
340
+ "fr-MA": "French (Morocco)",
341
+ "fr-MC": "French (Monaco)",
342
+ "fr-MF": "French (St. Martin)",
343
+ "fr-MG": "French (Madagascar)",
344
+ "fr-ML": "French (Mali)",
345
+ "fr-MQ": "French (Martinique)",
346
+ "fr-MR": "French (Mauritania)",
347
+ "fr-MU": "French (Mauritius)",
348
+ "fr-NC": "French (New Caledonia)",
349
+ "fr-NE": "French (Niger)",
350
+ "fr-PF": "French (French Polynesia)",
351
+ "fr-PM": "French (St. Pierre & Miquelon)",
352
+ "fr-RE": "French (R\u00e9union)",
353
+ "fr-RW": "French (Rwanda)",
354
+ "fr-SC": "French (Seychelles)",
355
+ "fr-SN": "French (Senegal)",
356
+ "fr-SY": "French (Syria)",
357
+ "fr-TD": "French (Chad)",
358
+ "fr-TG": "French (Togo)",
359
+ "fr-TN": "French (Tunisia)",
360
+ "fr-VU": "French (Vanuatu)",
361
+ "fr-WF": "French (Wallis & Futuna)",
362
+ "fr-YT": "French (Mayotte)",
363
+ "fur": "Friulian",
364
+ "fur-IT": "Friulian (Italy)",
365
+ "fy": "Western Frisian",
366
+ "fy-NL": "Western Frisian (Netherlands)",
367
+ "ga": "Irish",
368
+ "ga-GB": "Irish (United Kingdom)",
369
+ "ga-IE": "Irish (Ireland)",
370
+ "gd": "Scottish Gaelic",
371
+ "gd-GB": "Scottish Gaelic (United Kingdom)",
372
+ "gl": "Galician",
373
+ "gl-ES": "Galician (Spain)",
374
+ "gsw": "Swiss German",
375
+ "gsw-CH": "Swiss German (Switzerland)",
376
+ "gsw-FR": "Swiss German (France)",
377
+ "gsw-LI": "Swiss German (Liechtenstein)",
378
+ "gu": "Gujarati",
379
+ "gu-IN": "Gujarati (India)",
380
+ "guz": "Gusii",
381
+ "guz-KE": "Gusii (Kenya)",
382
+ "gv": "Manx",
383
+ "gv-IM": "Manx (Isle of Man)",
384
+ "ha": "Hausa",
385
+ "ha-GH": "Hausa (Ghana)",
386
+ "ha-NE": "Hausa (Niger)",
387
+ "ha-NG": "Hausa (Nigeria)",
388
+ "haw": "Hawaiian",
389
+ "haw-US": "Hawaiian (United States)",
390
+ "he": "Hebrew",
391
+ "he-IL": "Hebrew (Israel)",
392
+ "hi": "Hindi",
393
+ "hi-IN": "Hindi (India)",
394
+ "hr": "Croatian",
395
+ "hr-BA": "Croatian (Bosnia & Herzegovina)",
396
+ "hr-HR": "Croatian (Croatia)",
397
+ "hsb": "Upper Sorbian",
398
+ "hsb-DE": "Upper Sorbian (Germany)",
399
+ "hu": "Hungarian",
400
+ "hu-HU": "Hungarian (Hungary)",
401
+ "hy": "Armenian",
402
+ "hy-AM": "Armenian (Armenia)",
403
+ "ia": "Interlingua",
404
+ "ia-001": "Interlingua (World)",
405
+ "id": "Indonesian",
406
+ "id-ID": "Indonesian (Indonesia)",
407
+ "ig": "Igbo",
408
+ "ig-NG": "Igbo (Nigeria)",
409
+ "ii": "Sichuan Yi",
410
+ "ii-CN": "Sichuan Yi (China)",
411
+ "is": "Icelandic",
412
+ "is-IS": "Icelandic (Iceland)",
413
+ "it": "Italian",
414
+ "it-CH": "Italian (Switzerland)",
415
+ "it-IT": "Italian (Italy)",
416
+ "it-SM": "Italian (San Marino)",
417
+ "it-VA": "Italian (Vatican City)",
418
+ "ja": "Japanese",
419
+ "ja-JP": "Japanese (Japan)",
420
+ "jgo": "Ngomba",
421
+ "jgo-CM": "Ngomba (Cameroon)",
422
+ "jmc": "Machame",
423
+ "jmc-TZ": "Machame (Tanzania)",
424
+ "jv": "Javanese",
425
+ "jv-ID": "Javanese (Indonesia)",
426
+ "ka": "Georgian",
427
+ "ka-GE": "Georgian (Georgia)",
428
+ "kab": "Kabyle",
429
+ "kab-DZ": "Kabyle (Algeria)",
430
+ "kam": "Kamba",
431
+ "kam-KE": "Kamba (Kenya)",
432
+ "kde": "Makonde",
433
+ "kde-TZ": "Makonde (Tanzania)",
434
+ "kea": "Kabuverdianu",
435
+ "kea-CV": "Kabuverdianu (Cape Verde)",
436
+ "khq": "Koyra Chiini",
437
+ "khq-ML": "Koyra Chiini (Mali)",
438
+ "ki": "Kikuyu",
439
+ "ki-KE": "Kikuyu (Kenya)",
440
+ "kk": "Kazakh",
441
+ "kk-KZ": "Kazakh (Kazakhstan)",
442
+ "kkj": "Kako",
443
+ "kkj-CM": "Kako (Cameroon)",
444
+ "kl": "Kalaallisut",
445
+ "kl-GL": "Kalaallisut (Greenland)",
446
+ "kln": "Kalenjin",
447
+ "kln-KE": "Kalenjin (Kenya)",
448
+ "km": "Khmer",
449
+ "km-KH": "Khmer (Cambodia)",
450
+ "kn": "Kannada",
451
+ "kn-IN": "Kannada (India)",
452
+ "ko": "Korean",
453
+ "ko-KP": "Korean (North Korea)",
454
+ "ko-KR": "Korean (South Korea)",
455
+ "kok": "Konkani",
456
+ "kok-IN": "Konkani (India)",
457
+ "ks": "Kashmiri",
458
+ "ks-Arab": "Kashmiri (Arabic)",
459
+ "ks-IN": "Kashmiri (India)",
460
+ "ksb": "Shambala",
461
+ "ksb-TZ": "Shambala (Tanzania)",
462
+ "ksf": "Bafia",
463
+ "ksf-CM": "Bafia (Cameroon)",
464
+ "ksh": "Colognian",
465
+ "ksh-DE": "Colognian (Germany)",
466
+ "ku": "Kurdish",
467
+ "ku-TR": "Kurdish (Turkey)",
468
+ "kw": "Cornish",
469
+ "kw-GB": "Cornish (United Kingdom)",
470
+ "ky": "Kyrgyz",
471
+ "ky-KG": "Kyrgyz (Kyrgyzstan)",
472
+ "lag": "Langi",
473
+ "lag-TZ": "Langi (Tanzania)",
474
+ "lb": "Luxembourgish",
475
+ "lb-LU": "Luxembourgish (Luxembourg)",
476
+ "lg": "Ganda",
477
+ "lg-UG": "Ganda (Uganda)",
478
+ "lkt": "Lakota",
479
+ "lkt-US": "Lakota (United States)",
480
+ "ln": "Lingala",
481
+ "ln-AO": "Lingala (Angola)",
482
+ "ln-CD": "Lingala (Congo - Kinshasa)",
483
+ "ln-CF": "Lingala (Central African Republic)",
484
+ "ln-CG": "Lingala (Congo - Brazzaville)",
485
+ "lo": "Lao",
486
+ "lo-LA": "Lao (Laos)",
487
+ "lrc": "Northern Luri",
488
+ "lrc-IQ": "Northern Luri (Iraq)",
489
+ "lrc-IR": "Northern Luri (Iran)",
490
+ "lt": "Lithuanian",
491
+ "lt-LT": "Lithuanian (Lithuania)",
492
+ "lu": "Luba-Katanga",
493
+ "lu-CD": "Luba-Katanga (Congo - Kinshasa)",
494
+ "luo": "Luo (Kenya and Tanzania)",
495
+ "luo-KE": "Luo (Kenya and Tanzania) (Kenya)",
496
+ "luy": "Luyia",
497
+ "luy-KE": "Luyia (Kenya)",
498
+ "lv": "Latvian",
499
+ "lv-LV": "Latvian (Latvia)",
500
+ "mai": "Maithili",
501
+ "mai-IN": "Maithili (India)",
502
+ "mas": "Masai",
503
+ "mas-KE": "Masai (Kenya)",
504
+ "mas-TZ": "Masai (Tanzania)",
505
+ "mer": "Meru",
506
+ "mer-KE": "Meru (Kenya)",
507
+ "mfe": "Morisyen",
508
+ "mfe-MU": "Morisyen (Mauritius)",
509
+ "mg": "Malagasy",
510
+ "mg-MG": "Malagasy (Madagascar)",
511
+ "mgh": "Makhuwa-Meetto",
512
+ "mgh-MZ": "Makhuwa-Meetto (Mozambique)",
513
+ "mgo": "Meta\u02bc",
514
+ "mgo-CM": "Meta\u02bc (Cameroon)",
515
+ "mi": "Maori",
516
+ "mi-NZ": "Maori (New Zealand)",
517
+ "mk": "Macedonian",
518
+ "mk-MK": "Macedonian (North Macedonia)",
519
+ "ml": "Malayalam",
520
+ "ml-IN": "Malayalam (India)",
521
+ "mn": "Mongolian",
522
+ "mn-MN": "Mongolian (Mongolia)",
523
+ "mni": "Manipuri",
524
+ "mni-Beng": "Manipuri (Bangla)",
525
+ "mni-Beng-IN": "Manipuri (Bangla, India)",
526
+ "mr": "Marathi",
527
+ "mr-IN": "Marathi (India)",
528
+ "ms": "Malay",
529
+ "ms-BN": "Malay (Brunei)",
530
+ "ms-ID": "Malay (Indonesia)",
531
+ "ms-MY": "Malay (Malaysia)",
532
+ "ms-SG": "Malay (Singapore)",
533
+ "mt": "Maltese",
534
+ "mt-MT": "Maltese (Malta)",
535
+ "mua": "Mundang",
536
+ "mua-CM": "Mundang (Cameroon)",
537
+ "my": "Burmese",
538
+ "my-MM": "Burmese (Myanmar (Burma))",
539
+ "mzn": "Mazanderani",
540
+ "mzn-IR": "Mazanderani (Iran)",
541
+ "naq": "Nama",
542
+ "naq-NA": "Nama (Namibia)",
543
+ "nb": "Norwegian Bokm\u00e5l",
544
+ "nb-NO": "Norwegian Bokm\u00e5l (Norway)",
545
+ "nb-SJ": "Norwegian Bokm\u00e5l (Svalbard & Jan Mayen)",
546
+ "nd": "North Ndebele",
547
+ "nd-ZW": "North Ndebele (Zimbabwe)",
548
+ "nds": "Low German",
549
+ "nds-DE": "Low German (Germany)",
550
+ "nds-NL": "Low German (Netherlands)",
551
+ "ne": "Nepali",
552
+ "ne-IN": "Nepali (India)",
553
+ "ne-NP": "Nepali (Nepal)",
554
+ "nl": "Dutch",
555
+ "nl-AW": "Dutch (Aruba)",
556
+ "nl-BE": "Dutch (Belgium)",
557
+ "nl-BQ": "Dutch (Caribbean Netherlands)",
558
+ "nl-CW": "Dutch (Cura\u00e7ao)",
559
+ "nl-NL": "Dutch (Netherlands)",
560
+ "nl-SR": "Dutch (Suriname)",
561
+ "nl-SX": "Dutch (Sint Maarten)",
562
+ "nmg": "Kwasio",
563
+ "nmg-CM": "Kwasio (Cameroon)",
564
+ "nn": "Norwegian Nynorsk",
565
+ "nn-NO": "Norwegian Nynorsk (Norway)",
566
+ "nnh": "Ngiemboon",
567
+ "nnh-CM": "Ngiemboon (Cameroon)",
568
+ "nus": "Nuer",
569
+ "nus-SS": "Nuer (South Sudan)",
570
+ "nyn": "Nyankole",
571
+ "nyn-UG": "Nyankole (Uganda)",
572
+ "om": "Oromo",
573
+ "om-ET": "Oromo (Ethiopia)",
574
+ "om-KE": "Oromo (Kenya)",
575
+ "or": "Odia",
576
+ "or-IN": "Odia (India)",
577
+ "os": "Ossetic",
578
+ "os-GE": "Ossetic (Georgia)",
579
+ "os-RU": "Ossetic (Russia)",
580
+ "pa": "Punjabi",
581
+ "pa-Arab": "Punjabi (Arabic)",
582
+ "pa-Arab-PK": "Punjabi (Arabic, Pakistan)",
583
+ "pa-Guru": "Punjabi",
584
+ "pa-Guru-IN": "Punjabi (India)",
585
+ "pcm": "Nigerian Pidgin",
586
+ "pcm-NG": "Nigerian Pidgin (Nigeria)",
587
+ "pl": "Polish",
588
+ "pl-PL": "Polish (Poland)",
589
+ "prg": "Prussian",
590
+ "prg-001": "Prussian (World)",
591
+ "ps": "Pashto",
592
+ "ps-AF": "Pashto (Afghanistan)",
593
+ "ps-PK": "Pashto (Pakistan)",
594
+ "pt": "Portuguese",
595
+ "pt-AO": "Portuguese (Angola)",
596
+ "pt-BR": "Portuguese (Brazil)",
597
+ "pt-CH": "Portuguese (Switzerland)",
598
+ "pt-CV": "Portuguese (Cape Verde)",
599
+ "pt-GQ": "Portuguese (Equatorial Guinea)",
600
+ "pt-GW": "Portuguese (Guinea-Bissau)",
601
+ "pt-LU": "Portuguese (Luxembourg)",
602
+ "pt-MO": "Portuguese (Macao SAR China)",
603
+ "pt-MZ": "Portuguese (Mozambique)",
604
+ "pt-PT": "Portuguese (Portugal)",
605
+ "pt-ST": "Portuguese (S\u00e3o Tom\u00e9 & Pr\u00edncipe)",
606
+ "pt-TL": "Portuguese (Timor-Leste)",
607
+ "qu": "Quechua",
608
+ "qu-BO": "Quechua (Bolivia)",
609
+ "qu-EC": "Quechua (Ecuador)",
610
+ "qu-PE": "Quechua (Peru)",
611
+ "rm": "Romansh",
612
+ "rm-CH": "Romansh (Switzerland)",
613
+ "rn": "Rundi",
614
+ "rn-BI": "Rundi (Burundi)",
615
+ "ro": "Romanian",
616
+ "ro-MD": "Romanian (Moldova)",
617
+ "ro-RO": "Romanian (Romania)",
618
+ "rof": "Rombo",
619
+ "rof-TZ": "Rombo (Tanzania)",
620
+ "und": "Unknown language",
621
+ "ru": "Russian",
622
+ "ru-BY": "Russian (Belarus)",
623
+ "ru-KG": "Russian (Kyrgyzstan)",
624
+ "ru-KZ": "Russian (Kazakhstan)",
625
+ "ru-MD": "Russian (Moldova)",
626
+ "ru-RU": "Russian (Russia)",
627
+ "ru-UA": "Russian (Ukraine)",
628
+ "rw": "Kinyarwanda",
629
+ "rw-RW": "Kinyarwanda (Rwanda)",
630
+ "rwk": "Rwa",
631
+ "rwk-TZ": "Rwa (Tanzania)",
632
+ "sah": "Sakha",
633
+ "sah-RU": "Sakha (Russia)",
634
+ "saq": "Samburu",
635
+ "saq-KE": "Samburu (Kenya)",
636
+ "sat": "Santali",
637
+ "sat-Olck": "Santali (Ol Chiki)",
638
+ "sat-Olck-IN": "Santali (Ol Chiki, India)",
639
+ "sbp": "Sangu",
640
+ "sbp-TZ": "Sangu (Tanzania)",
641
+ "sd": "Sindhi",
642
+ "sd-Arab": "Sindhi (Arabic)",
643
+ "sd-Arab-PK": "Sindhi (Arabic, Pakistan)",
644
+ "sd-Deva": "Sindhi (Devanagari)",
645
+ "sd-Deva-IN": "Sindhi (Devanagari, India)",
646
+ "se": "Northern Sami",
647
+ "se-FI": "Northern Sami (Finland)",
648
+ "se-NO": "Northern Sami (Norway)",
649
+ "se-SE": "Northern Sami (Sweden)",
650
+ "seh": "Sena",
651
+ "seh-MZ": "Sena (Mozambique)",
652
+ "ses": "Koyraboro Senni",
653
+ "ses-ML": "Koyraboro Senni (Mali)",
654
+ "sg": "Sango",
655
+ "sg-CF": "Sango (Central African Republic)",
656
+ "shi": "Tachelhit",
657
+ "shi-Latn": "Tachelhit (Latin)",
658
+ "shi-Latn-MA": "Tachelhit (Latin, Morocco)",
659
+ "shi-Tfng": "Tachelhit (Tifinagh)",
660
+ "shi-Tfng-MA": "Tachelhit (Tifinagh, Morocco)",
661
+ "si": "Sinhala",
662
+ "si-LK": "Sinhala (Sri Lanka)",
663
+ "sk": "Slovak",
664
+ "sk-SK": "Slovak (Slovakia)",
665
+ "sl": "Slovenian",
666
+ "sl-SI": "Slovenian (Slovenia)",
667
+ "smn": "Inari Sami",
668
+ "smn-FI": "Inari Sami (Finland)",
669
+ "sn": "Shona",
670
+ "sn-ZW": "Shona (Zimbabwe)",
671
+ "so": "Somali",
672
+ "so-DJ": "Somali (Djibouti)",
673
+ "so-ET": "Somali (Ethiopia)",
674
+ "so-KE": "Somali (Kenya)",
675
+ "so-SO": "Somali (Somalia)",
676
+ "sq": "Albanian",
677
+ "sq-AL": "Albanian (Albania)",
678
+ "sq-MK": "Albanian (North Macedonia)",
679
+ "sq-XK": "Albanian (Kosovo)",
680
+ "sr": "Serbian",
681
+ "sr-Cyrl": "Serbian (Cyrillic)",
682
+ "sr-Cyrl-BA": "Serbian (Cyrillic, Bosnia & Herzegovina)",
683
+ "sr-Cyrl-ME": "Serbian (Cyrillic, Montenegro)",
684
+ "sr-Cyrl-RS": "Serbian (Cyrillic, Serbia)",
685
+ "sr-Cyrl-XK": "Serbian (Cyrillic, Kosovo)",
686
+ "sr-Latn": "Serbian (Latin)",
687
+ "sr-Latn-BA": "Serbian (Latin, Bosnia & Herzegovina)",
688
+ "sr-Latn-ME": "Serbian (Latin, Montenegro)",
689
+ "sr-Latn-RS": "Serbian (Latin, Serbia)",
690
+ "sr-Latn-XK": "Serbian (Latin, Kosovo)",
691
+ "su": "Sundanese",
692
+ "su-Latn": "Sundanese (Latin)",
693
+ "su-Latn-ID": "Sundanese (Latin, Indonesia)",
694
+ "sv": "Swedish",
695
+ "sv-AX": "Swedish (\u00c5land Islands)",
696
+ "sv-FI": "Swedish (Finland)",
697
+ "sv-SE": "Swedish (Sweden)",
698
+ "sw": "Swahili",
699
+ "sw-CD": "Swahili (Congo - Kinshasa)",
700
+ "sw-KE": "Swahili (Kenya)",
701
+ "sw-TZ": "Swahili (Tanzania)",
702
+ "sw-UG": "Swahili (Uganda)",
703
+ "ta": "Tamil",
704
+ "ta-IN": "Tamil (India)",
705
+ "ta-LK": "Tamil (Sri Lanka)",
706
+ "ta-MY": "Tamil (Malaysia)",
707
+ "ta-SG": "Tamil (Singapore)",
708
+ "te": "Telugu",
709
+ "te-IN": "Telugu (India)",
710
+ "teo": "Teso",
711
+ "teo-KE": "Teso (Kenya)",
712
+ "teo-UG": "Teso (Uganda)",
713
+ "tg": "Tajik",
714
+ "tg-TJ": "Tajik (Tajikistan)",
715
+ "th": "Thai",
716
+ "th-TH": "Thai (Thailand)",
717
+ "ti": "Tigrinya",
718
+ "ti-ER": "Tigrinya (Eritrea)",
719
+ "ti-ET": "Tigrinya (Ethiopia)",
720
+ "tk": "Turkmen",
721
+ "tk-TM": "Turkmen (Turkmenistan)",
722
+ "to": "Tongan",
723
+ "to-TO": "Tongan (Tonga)",
724
+ "tr": "Turkish",
725
+ "tr-CY": "Turkish (Cyprus)",
726
+ "tr-TR": "Turkish (Turkey)",
727
+ "tt": "Tatar",
728
+ "tt-RU": "Tatar (Russia)",
729
+ "twq": "Tasawaq",
730
+ "twq-NE": "Tasawaq (Niger)",
731
+ "tzm": "Central Atlas Tamazight",
732
+ "tzm-MA": "Central Atlas Tamazight (Morocco)",
733
+ "ug": "Uyghur",
734
+ "ug-CN": "Uyghur (China)",
735
+ "uk": "Ukrainian",
736
+ "uk-UA": "Ukrainian (Ukraine)",
737
+ "ur": "Urdu",
738
+ "ur-IN": "Urdu (India)",
739
+ "ur-PK": "Urdu (Pakistan)",
740
+ "uz": "Uzbek",
741
+ "uz-Arab": "Uzbek (Arabic)",
742
+ "uz-Arab-AF": "Uzbek (Arabic, Afghanistan)",
743
+ "uz-Cyrl": "Uzbek (Cyrillic)",
744
+ "uz-Cyrl-UZ": "Uzbek (Cyrillic, Uzbekistan)",
745
+ "uz-Latn": "Uzbek (Latin)",
746
+ "uz-Latn-UZ": "Uzbek (Latin, Uzbekistan)",
747
+ "vai": "Vai",
748
+ "vai-Latn": "Vai (Latin)",
749
+ "vai-Latn-LR": "Vai (Latin, Liberia)",
750
+ "vai-Vaii": "Vai (Vai)",
751
+ "vai-Vaii-LR": "Vai (Vai, Liberia)",
752
+ "vi": "Vietnamese",
753
+ "vi-VN": "Vietnamese (Vietnam)",
754
+ "vo": "Volap\u00fck",
755
+ "vo-001": "Volap\u00fck (World)",
756
+ "vun": "Vunjo",
757
+ "vun-TZ": "Vunjo (Tanzania)",
758
+ "wae": "Walser",
759
+ "wae-CH": "Walser (Switzerland)",
760
+ "wo": "Wolof",
761
+ "wo-SN": "Wolof (Senegal)",
762
+ "xh": "Xhosa",
763
+ "xh-ZA": "Xhosa (South Africa)",
764
+ "xog": "Soga",
765
+ "xog-UG": "Soga (Uganda)",
766
+ "yav": "Yangben",
767
+ "yav-CM": "Yangben (Cameroon)",
768
+ "yi": "Yiddish",
769
+ "yi-001": "Yiddish (World)",
770
+ "yo": "Yoruba",
771
+ "yo-BJ": "Yoruba (Benin)",
772
+ "yo-NG": "Yoruba (Nigeria)",
773
+ "yue": "Cantonese",
774
+ "yue-Hans": "Cantonese (Simplified)",
775
+ "yue-Hans-CN": "Cantonese (Simplified, China)",
776
+ "yue-Hant": "Cantonese (Traditional)",
777
+ "yue-Hant-HK": "Cantonese (Traditional, Hong Kong SAR China)",
778
+ "zgh": "Standard Moroccan Tamazight",
779
+ "zgh-MA": "Standard Moroccan Tamazight (Morocco)",
780
+ "zh": "Chinese",
781
+ "zh-Hans": "Chinese (Simplified)",
782
+ "zh-Hans-CN": "Chinese (Simplified, China)",
783
+ "zh-Hans-HK": "Chinese (Simplified, Hong Kong SAR China)",
784
+ "zh-Hans-MO": "Chinese (Simplified, Macao SAR China)",
785
+ "zh-Hans-SG": "Chinese (Simplified, Singapore)",
786
+ "zh-Hant": "Chinese (Traditional)",
787
+ "zh-Hant-HK": "Chinese (Traditional, Hong Kong SAR China)",
788
+ "zh-Hant-MO": "Chinese (Traditional, Macao SAR China)",
789
+ "zh-Hant-TW": "Chinese (Traditional, Taiwan)",
790
+ "zu": "Zulu",
791
+ "zu-ZA": "Zulu (South Africa)"
792
+ }
licenses.json ADDED
@@ -0,0 +1,452 @@
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
+ {
2
+ "other": "Other license",
3
+ "unknown": "License information unavailable",
4
+ "0bsd": "BSD Zero Clause License",
5
+ "aal": "Attribution Assurance License",
6
+ "abstyles": "Abstyles License",
7
+ "adobe-2006": "Adobe Systems Incorporated Source Code License Agreement",
8
+ "adobe-glyph": "Adobe Glyph List License",
9
+ "adsl": "Amazon Digital Services License",
10
+ "afl-1.1": "Academic Free License v1.1",
11
+ "afl-1.2": "Academic Free License v1.2",
12
+ "afl-2.0": "Academic Free License v2.0",
13
+ "afl-2.1": "Academic Free License v2.1",
14
+ "afl-3.0": "Academic Free License v3.0",
15
+ "afmparse": "Afmparse License",
16
+ "agpl-1.0": "Affero General Public License v1.0",
17
+ "agpl-1.0-only": "Affero General Public License v1.0 only",
18
+ "agpl-1.0-or-later": "Affero General Public License v1.0 or later",
19
+ "agpl-3.0": "GNU Affero General Public License v3.0",
20
+ "agpl-3.0-only": "GNU Affero General Public License v3.0 only",
21
+ "agpl-3.0-or-later": "GNU Affero General Public License v3.0 or later",
22
+ "aladdin": "Aladdin Free Public License",
23
+ "amdplpa": "AMD's plpa_map.c License",
24
+ "aml": "Apple MIT License",
25
+ "ampas": "Academy of Motion Picture Arts and Sciences BSD",
26
+ "antlr-pd": "ANTLR Software Rights Notice",
27
+ "antlr-pd-fallback": "ANTLR Software Rights Notice with license fallback",
28
+ "apache-1.0": "Apache License 1.0",
29
+ "apache-1.1": "Apache License 1.1",
30
+ "apache-2.0": "Apache License 2.0",
31
+ "apafml": "Adobe Postscript AFM License",
32
+ "apl-1.0": "Adaptive Public License 1.0",
33
+ "apsl-1.0": "Apple Public Source License 1.0",
34
+ "apsl-1.1": "Apple Public Source License 1.1",
35
+ "apsl-1.2": "Apple Public Source License 1.2",
36
+ "apsl-2.0": "Apple Public Source License 2.0",
37
+ "artistic-1.0": "Artistic License 1.0",
38
+ "artistic-1.0-cl8": "Artistic License 1.0 w/clause 8",
39
+ "artistic-1.0-perl": "Artistic License 1.0 (Perl)",
40
+ "artistic-2.0": "Artistic License 2.0",
41
+ "bahyph": "Bahyph License",
42
+ "barr": "Barr License",
43
+ "beerware": "Beerware License",
44
+ "bittorrent-1.0": "BitTorrent Open Source License v1.0",
45
+ "bittorrent-1.1": "BitTorrent Open Source License v1.1",
46
+ "blessing": "SQLite Blessing",
47
+ "blueoak-1.0.0": "Blue Oak Model License 1.0.0",
48
+ "borceux": "Borceux license",
49
+ "bsd-1-clause": "BSD 1-Clause License",
50
+ "bsd-2-clause": "BSD 2-Clause \"Simplified\" License",
51
+ "bsd-2-clause-freebsd": "BSD 2-Clause FreeBSD License",
52
+ "bsd-2-clause-netbsd": "BSD 2-Clause NetBSD License",
53
+ "bsd-2-clause-patent": "BSD-2-Clause Plus Patent License",
54
+ "bsd-2-clause-views": "BSD 2-Clause with views sentence",
55
+ "bsd-3-clause": "BSD 3-Clause \"New\" or \"Revised\" License",
56
+ "bsd-3-clause-attribution": "BSD with attribution",
57
+ "bsd-3-clause-clear": "BSD 3-Clause Clear License",
58
+ "bsd-3-clause-lbnl": "Lawrence Berkeley National Labs BSD variant license",
59
+ "bsd-3-clause-no-nuclear-license": "BSD 3-Clause No Nuclear License",
60
+ "bsd-3-clause-no-nuclear-license-2014": "BSD 3-Clause No Nuclear License 2014",
61
+ "bsd-3-clause-no-nuclear-warranty": "BSD 3-Clause No Nuclear Warranty",
62
+ "bsd-3-clause-open-mpi": "BSD 3-Clause Open MPI variant",
63
+ "bsd-4-clause": "BSD 4-Clause \"Original\" or \"Old\" License",
64
+ "bsd-4-clause-uc": "BSD-4-Clause (University of California-Specific)",
65
+ "bsd-protection": "BSD Protection License",
66
+ "bsd-source-code": "BSD Source Code Attribution",
67
+ "bsl-1.0": "Boost Software License 1.0",
68
+ "busl-1.1": "Business Source License 1.1",
69
+ "bzip2-1.0.5": "bzip2 and libbzip2 License v1.0.5",
70
+ "bzip2-1.0.6": "bzip2 and libbzip2 License v1.0.6",
71
+ "cal-1.0": "Cryptographic Autonomy License 1.0",
72
+ "cal-1.0-combined-work-exception": "Cryptographic Autonomy License 1.0 (Combined Work Exception)",
73
+ "caldera": "Caldera License",
74
+ "catosl-1.1": "Computer Associates Trusted Open Source License 1.1",
75
+ "cc-by-1.0": "Creative Commons Attribution 1.0 Generic",
76
+ "cc-by-2.0": "Creative Commons Attribution 2.0 Generic",
77
+ "cc-by-2.5": "Creative Commons Attribution 2.5 Generic",
78
+ "cc-by-3.0": "Creative Commons Attribution 3.0 Unported",
79
+ "cc-by-3.0-at": "Creative Commons Attribution 3.0 Austria",
80
+ "cc-by-3.0-us": "Creative Commons Attribution 3.0 United States",
81
+ "cc-by-4.0": "Creative Commons Attribution 4.0 International",
82
+ "cc-by-nc-1.0": "Creative Commons Attribution Non Commercial 1.0 Generic",
83
+ "cc-by-nc-2.0": "Creative Commons Attribution Non Commercial 2.0 Generic",
84
+ "cc-by-nc-2.5": "Creative Commons Attribution Non Commercial 2.5 Generic",
85
+ "cc-by-nc-3.0": "Creative Commons Attribution Non Commercial 3.0 Unported",
86
+ "cc-by-nc-4.0": "Creative Commons Attribution Non Commercial 4.0 International",
87
+ "cc-by-nc-nd-1.0": "Creative Commons Attribution Non Commercial No Derivatives 1.0 Generic",
88
+ "cc-by-nc-nd-2.0": "Creative Commons Attribution Non Commercial No Derivatives 2.0 Generic",
89
+ "cc-by-nc-nd-2.5": "Creative Commons Attribution Non Commercial No Derivatives 2.5 Generic",
90
+ "cc-by-nc-nd-3.0": "Creative Commons Attribution Non Commercial No Derivatives 3.0 Unported",
91
+ "cc-by-nc-nd-3.0-igo": "Creative Commons Attribution Non Commercial No Derivatives 3.0 IGO",
92
+ "cc-by-nc-nd-4.0": "Creative Commons Attribution Non Commercial No Derivatives 4.0 International",
93
+ "cc-by-nc-sa-1.0": "Creative Commons Attribution Non Commercial Share Alike 1.0 Generic",
94
+ "cc-by-nc-sa-2.0": "Creative Commons Attribution Non Commercial Share Alike 2.0 Generic",
95
+ "cc-by-nc-sa-2.5": "Creative Commons Attribution Non Commercial Share Alike 2.5 Generic",
96
+ "cc-by-nc-sa-3.0": "Creative Commons Attribution Non Commercial Share Alike 3.0 Unported",
97
+ "cc-by-nc-sa-4.0": "Creative Commons Attribution Non Commercial Share Alike 4.0 International",
98
+ "cc-by-nd-1.0": "Creative Commons Attribution No Derivatives 1.0 Generic",
99
+ "cc-by-nd-2.0": "Creative Commons Attribution No Derivatives 2.0 Generic",
100
+ "cc-by-nd-2.5": "Creative Commons Attribution No Derivatives 2.5 Generic",
101
+ "cc-by-nd-3.0": "Creative Commons Attribution No Derivatives 3.0 Unported",
102
+ "cc-by-nd-4.0": "Creative Commons Attribution No Derivatives 4.0 International",
103
+ "cc-by-sa-1.0": "Creative Commons Attribution Share Alike 1.0 Generic",
104
+ "cc-by-sa-2.0": "Creative Commons Attribution Share Alike 2.0 Generic",
105
+ "cc-by-sa-2.0-uk": "Creative Commons Attribution Share Alike 2.0 England and Wales",
106
+ "cc-by-sa-2.5": "Creative Commons Attribution Share Alike 2.5 Generic",
107
+ "cc-by-sa-3.0": "Creative Commons Attribution Share Alike 3.0 Unported",
108
+ "cc-by-sa-3.0-at": "Creative Commons Attribution-Share Alike 3.0 Austria",
109
+ "cc-by-sa-4.0": "Creative Commons Attribution Share Alike 4.0 International",
110
+ "cc-pddc": "Creative Commons Public Domain Dedication and Certification",
111
+ "cc0-1.0": "Creative Commons Zero v1.0 Universal",
112
+ "cddl-1.0": "Common Development and Distribution License 1.0",
113
+ "cddl-1.1": "Common Development and Distribution License 1.1",
114
+ "cdla-permissive-1.0": "Community Data License Agreement Permissive 1.0",
115
+ "cdla-sharing-1.0": "Community Data License Agreement Sharing 1.0",
116
+ "cecill-1.0": "CeCILL Free Software License Agreement v1.0",
117
+ "cecill-1.1": "CeCILL Free Software License Agreement v1.1",
118
+ "cecill-2.0": "CeCILL Free Software License Agreement v2.0",
119
+ "cecill-2.1": "CeCILL Free Software License Agreement v2.1",
120
+ "cecill-b": "CeCILL-B Free Software License Agreement",
121
+ "cecill-c": "CeCILL-C Free Software License Agreement",
122
+ "cern-ohl-1.1": "CERN Open Hardware Licence v1.1",
123
+ "cern-ohl-1.2": "CERN Open Hardware Licence v1.2",
124
+ "cern-ohl-p-2.0": "CERN Open Hardware Licence Version 2 - Permissive",
125
+ "cern-ohl-s-2.0": "CERN Open Hardware Licence Version 2 - Strongly Reciprocal",
126
+ "cern-ohl-w-2.0": "CERN Open Hardware Licence Version 2 - Weakly Reciprocal",
127
+ "clartistic": "Clarified Artistic License",
128
+ "cnri-jython": "CNRI Jython License",
129
+ "cnri-python": "CNRI Python License",
130
+ "cnri-python-gpl-compatible": "CNRI Python Open Source GPL Compatible License Agreement",
131
+ "condor-1.1": "Condor Public License v1.1",
132
+ "copyleft-next-0.3.0": "copyleft-next 0.3.0",
133
+ "copyleft-next-0.3.1": "copyleft-next 0.3.1",
134
+ "cpal-1.0": "Common Public Attribution License 1.0",
135
+ "cpl-1.0": "Common Public License 1.0",
136
+ "cpol-1.02": "Code Project Open License 1.02",
137
+ "crossword": "Crossword License",
138
+ "crystalstacker": "CrystalStacker License",
139
+ "cua-opl-1.0": "CUA Office Public License v1.0",
140
+ "cube": "Cube License",
141
+ "curl": "curl License",
142
+ "d-fsl-1.0": "Deutsche Freie Software Lizenz",
143
+ "diffmark": "diffmark license",
144
+ "doc": "DOC License",
145
+ "dotseqn": "Dotseqn License",
146
+ "dsdp": "DSDP License",
147
+ "dvipdfm": "dvipdfm License",
148
+ "ecl-1.0": "Educational Community License v1.0",
149
+ "ecl-2.0": "Educational Community License v2.0",
150
+ "ecos-2.0": "eCos license version 2.0",
151
+ "efl-1.0": "Eiffel Forum License v1.0",
152
+ "efl-2.0": "Eiffel Forum License v2.0",
153
+ "egenix": "eGenix.com Public License 1.1.0",
154
+ "entessa": "Entessa Public License v1.0",
155
+ "epics": "EPICS Open License",
156
+ "epl-1.0": "Eclipse Public License 1.0",
157
+ "epl-2.0": "Eclipse Public License 2.0",
158
+ "erlpl-1.1": "Erlang Public License v1.1",
159
+ "etalab-2.0": "Etalab Open License 2.0",
160
+ "eudatagrid": "EU DataGrid Software License",
161
+ "eupl-1.0": "European Union Public License 1.0",
162
+ "eupl-1.1": "European Union Public License 1.1",
163
+ "eupl-1.2": "European Union Public License 1.2",
164
+ "eurosym": "Eurosym License",
165
+ "fair": "Fair License",
166
+ "frameworx-1.0": "Frameworx Open License 1.0",
167
+ "freeimage": "FreeImage Public License v1.0",
168
+ "fsfap": "FSF All Permissive License",
169
+ "fsful": "FSF Unlimited License",
170
+ "fsfullr": "FSF Unlimited License (with License Retention)",
171
+ "ftl": "Freetype Project License",
172
+ "gfdl-1.1": "GNU Free Documentation License v1.1",
173
+ "gfdl-1.1-invariants-only": "GNU Free Documentation License v1.1 only - invariants",
174
+ "gfdl-1.1-invariants-or-later": "GNU Free Documentation License v1.1 or later - invariants",
175
+ "gfdl-1.1-no-invariants-only": "GNU Free Documentation License v1.1 only - no invariants",
176
+ "gfdl-1.1-no-invariants-or-later": "GNU Free Documentation License v1.1 or later - no invariants",
177
+ "gfdl-1.1-only": "GNU Free Documentation License v1.1 only",
178
+ "gfdl-1.1-or-later": "GNU Free Documentation License v1.1 or later",
179
+ "gfdl-1.2": "GNU Free Documentation License v1.2",
180
+ "gfdl-1.2-invariants-only": "GNU Free Documentation License v1.2 only - invariants",
181
+ "gfdl-1.2-invariants-or-later": "GNU Free Documentation License v1.2 or later - invariants",
182
+ "gfdl-1.2-no-invariants-only": "GNU Free Documentation License v1.2 only - no invariants",
183
+ "gfdl-1.2-no-invariants-or-later": "GNU Free Documentation License v1.2 or later - no invariants",
184
+ "gfdl-1.2-only": "GNU Free Documentation License v1.2 only",
185
+ "gfdl-1.2-or-later": "GNU Free Documentation License v1.2 or later",
186
+ "gfdl-1.3": "GNU Free Documentation License v1.3",
187
+ "gfdl-1.3-invariants-only": "GNU Free Documentation License v1.3 only - invariants",
188
+ "gfdl-1.3-invariants-or-later": "GNU Free Documentation License v1.3 or later - invariants",
189
+ "gfdl-1.3-no-invariants-only": "GNU Free Documentation License v1.3 only - no invariants",
190
+ "gfdl-1.3-no-invariants-or-later": "GNU Free Documentation License v1.3 or later - no invariants",
191
+ "gfdl-1.3-only": "GNU Free Documentation License v1.3 only",
192
+ "gfdl-1.3-or-later": "GNU Free Documentation License v1.3 or later",
193
+ "giftware": "Giftware License",
194
+ "gl2ps": "GL2PS License",
195
+ "glide": "3dfx Glide License",
196
+ "glulxe": "Glulxe License",
197
+ "glwtpl": "Good Luck With That Public License",
198
+ "gnuplot": "gnuplot License",
199
+ "gpl-1.0": "GNU General Public License v1.0 only",
200
+ "gpl-1.0+": "GNU General Public License v1.0 or later",
201
+ "gpl-1.0-only": "GNU General Public License v1.0 only",
202
+ "gpl-1.0-or-later": "GNU General Public License v1.0 or later",
203
+ "gpl-2.0": "GNU General Public License v2.0 only",
204
+ "gpl-2.0+": "GNU General Public License v2.0 or later",
205
+ "gpl-2.0-only": "GNU General Public License v2.0 only",
206
+ "gpl-2.0-or-later": "GNU General Public License v2.0 or later",
207
+ "gpl-2.0-with-autoconf-exception": "GNU General Public License v2.0 w/Autoconf exception",
208
+ "gpl-2.0-with-bison-exception": "GNU General Public License v2.0 w/Bison exception",
209
+ "gpl-2.0-with-classpath-exception": "GNU General Public License v2.0 w/Classpath exception",
210
+ "gpl-2.0-with-font-exception": "GNU General Public License v2.0 w/Font exception",
211
+ "gpl-2.0-with-gcc-exception": "GNU General Public License v2.0 w/GCC Runtime Library exception",
212
+ "gpl-3.0": "GNU General Public License v3.0 only",
213
+ "gpl-3.0+": "GNU General Public License v3.0 or later",
214
+ "gpl-3.0-only": "GNU General Public License v3.0 only",
215
+ "gpl-3.0-or-later": "GNU General Public License v3.0 or later",
216
+ "gpl-3.0-with-autoconf-exception": "GNU General Public License v3.0 w/Autoconf exception",
217
+ "gpl-3.0-with-gcc-exception": "GNU General Public License v3.0 w/GCC Runtime Library exception",
218
+ "gsoap-1.3b": "gSOAP Public License v1.3b",
219
+ "haskellreport": "Haskell Language Report License",
220
+ "hippocratic-2.1": "Hippocratic License 2.1",
221
+ "hpnd": "Historical Permission Notice and Disclaimer",
222
+ "hpnd-sell-variant": "Historical Permission Notice and Disclaimer - sell variant",
223
+ "htmltidy": "HTML Tidy License",
224
+ "ibm-pibs": "IBM PowerPC Initialization and Boot Software",
225
+ "icu": "ICU License",
226
+ "ijg": "Independent JPEG Group License",
227
+ "imagemagick": "ImageMagick License",
228
+ "imatix": "iMatix Standard Function Library Agreement",
229
+ "imlib2": "Imlib2 License",
230
+ "info-zip": "Info-ZIP License",
231
+ "intel": "Intel Open Source License",
232
+ "intel-acpi": "Intel ACPI Software License Agreement",
233
+ "interbase-1.0": "Interbase Public License v1.0",
234
+ "ipa": "IPA Font License",
235
+ "ipl-1.0": "IBM Public License v1.0",
236
+ "isc": "ISC License",
237
+ "jasper-2.0": "JasPer License",
238
+ "jpnic": "Japan Network Information Center License",
239
+ "json": "JSON License",
240
+ "lal-1.2": "Licence Art Libre 1.2",
241
+ "lal-1.3": "Licence Art Libre 1.3",
242
+ "latex2e": "Latex2e License",
243
+ "leptonica": "Leptonica License",
244
+ "lgpl-2.0": "GNU Library General Public License v2 only",
245
+ "lgpl-2.0+": "GNU Library General Public License v2 or later",
246
+ "lgpl-2.0-only": "GNU Library General Public License v2 only",
247
+ "lgpl-2.0-or-later": "GNU Library General Public License v2 or later",
248
+ "lgpl-2.1": "GNU Lesser General Public License v2.1 only",
249
+ "lgpl-2.1+": "GNU Library General Public License v2.1 or later",
250
+ "lgpl-2.1-only": "GNU Lesser General Public License v2.1 only",
251
+ "lgpl-2.1-or-later": "GNU Lesser General Public License v2.1 or later",
252
+ "lgpl-3.0": "GNU Lesser General Public License v3.0 only",
253
+ "lgpl-3.0+": "GNU Lesser General Public License v3.0 or later",
254
+ "lgpl-3.0-only": "GNU Lesser General Public License v3.0 only",
255
+ "lgpl-3.0-or-later": "GNU Lesser General Public License v3.0 or later",
256
+ "lgpllr": "Lesser General Public License For Linguistic Resources",
257
+ "libpng": "libpng License",
258
+ "libpng-2.0": "PNG Reference Library version 2",
259
+ "libselinux-1.0": "libselinux public domain notice",
260
+ "libtiff": "libtiff License",
261
+ "liliq-p-1.1": "Licence Libre du Qu\u00e9bec \u2013 Permissive version 1.1",
262
+ "liliq-r-1.1": "Licence Libre du Qu\u00e9bec \u2013 R\u00e9ciprocit\u00e9 version 1.1",
263
+ "liliq-rplus-1.1": "Licence Libre du Qu\u00e9bec \u2013 R\u00e9ciprocit\u00e9 forte version 1.1",
264
+ "linux-openib": "Linux Kernel Variant of OpenIB.org license",
265
+ "lpl-1.0": "Lucent Public License Version 1.0",
266
+ "lpl-1.02": "Lucent Public License v1.02",
267
+ "lppl-1.0": "LaTeX Project Public License v1.0",
268
+ "lppl-1.1": "LaTeX Project Public License v1.1",
269
+ "lppl-1.2": "LaTeX Project Public License v1.2",
270
+ "lppl-1.3a": "LaTeX Project Public License v1.3a",
271
+ "lppl-1.3c": "LaTeX Project Public License v1.3c",
272
+ "makeindex": "MakeIndex License",
273
+ "miros": "The MirOS Licence",
274
+ "mit": "MIT License",
275
+ "mit-0": "MIT No Attribution",
276
+ "mit-advertising": "Enlightenment License (e16)",
277
+ "mit-cmu": "CMU License",
278
+ "mit-enna": "enna License",
279
+ "mit-feh": "feh License",
280
+ "mit-open-group": "MIT Open Group variant",
281
+ "mitnfa": "MIT +no-false-attribs license",
282
+ "motosoto": "Motosoto License",
283
+ "mpich2": "mpich2 License",
284
+ "mpl-1.0": "Mozilla Public License 1.0",
285
+ "mpl-1.1": "Mozilla Public License 1.1",
286
+ "mpl-2.0": "Mozilla Public License 2.0",
287
+ "mpl-2.0-no-copyleft-exception": "Mozilla Public License 2.0 (no copyleft exception)",
288
+ "ms-pl": "Microsoft Public License",
289
+ "ms-rl": "Microsoft Reciprocal License",
290
+ "mtll": "Matrix Template Library License",
291
+ "mulanpsl-1.0": "Mulan Permissive Software License, Version 1",
292
+ "mulanpsl-2.0": "Mulan Permissive Software License, Version 2",
293
+ "multics": "Multics License",
294
+ "mup": "Mup License",
295
+ "nasa-1.3": "NASA Open Source Agreement 1.3",
296
+ "naumen": "Naumen Public License",
297
+ "nbpl-1.0": "Net Boolean Public License v1",
298
+ "ncgl-uk-2.0": "Non-Commercial Government Licence",
299
+ "ncsa": "University of Illinois/NCSA Open Source License",
300
+ "net-snmp": "Net-SNMP License",
301
+ "netcdf": "NetCDF license",
302
+ "newsletr": "Newsletr License",
303
+ "ngpl": "Nethack General Public License",
304
+ "nist-pd": "NIST Public Domain Notice",
305
+ "nist-pd-fallback": "NIST Public Domain Notice with license fallback",
306
+ "nlod-1.0": "Norwegian Licence for Open Government Data",
307
+ "nlpl": "No Limit Public License",
308
+ "nokia": "Nokia Open Source License",
309
+ "nosl": "Netizen Open Source License",
310
+ "noweb": "Noweb License",
311
+ "npl-1.0": "Netscape Public License v1.0",
312
+ "npl-1.1": "Netscape Public License v1.1",
313
+ "nposl-3.0": "Non-Profit Open Software License 3.0",
314
+ "nrl": "NRL License",
315
+ "ntp": "NTP License",
316
+ "ntp-0": "NTP No Attribution",
317
+ "nunit": "Nunit License",
318
+ "o-uda-1.0": "Open Use of Data Agreement v1.0",
319
+ "occt-pl": "Open CASCADE Technology Public License",
320
+ "oclc-2.0": "OCLC Research Public License 2.0",
321
+ "odbl-1.0": "ODC Open Database License v1.0",
322
+ "odc-by-1.0": "Open Data Commons Attribution License v1.0",
323
+ "ofl-1.0": "SIL Open Font License 1.0",
324
+ "ofl-1.0-no-rfn": "SIL Open Font License 1.0 with no Reserved Font Name",
325
+ "ofl-1.0-rfn": "SIL Open Font License 1.0 with Reserved Font Name",
326
+ "ofl-1.1": "SIL Open Font License 1.1",
327
+ "ofl-1.1-no-rfn": "SIL Open Font License 1.1 with no Reserved Font Name",
328
+ "ofl-1.1-rfn": "SIL Open Font License 1.1 with Reserved Font Name",
329
+ "ogc-1.0": "OGC Software License, Version 1.0",
330
+ "ogl-canada-2.0": "Open Government Licence - Canada",
331
+ "ogl-uk-1.0": "Open Government Licence v1.0",
332
+ "ogl-uk-2.0": "Open Government Licence v2.0",
333
+ "ogl-uk-3.0": "Open Government Licence v3.0",
334
+ "ogtsl": "Open Group Test Suite License",
335
+ "oldap-1.1": "Open LDAP Public License v1.1",
336
+ "oldap-1.2": "Open LDAP Public License v1.2",
337
+ "oldap-1.3": "Open LDAP Public License v1.3",
338
+ "oldap-1.4": "Open LDAP Public License v1.4",
339
+ "oldap-2.0": "Open LDAP Public License v2.0 (or possibly 2.0A and 2.0B)",
340
+ "oldap-2.0.1": "Open LDAP Public License v2.0.1",
341
+ "oldap-2.1": "Open LDAP Public License v2.1",
342
+ "oldap-2.2": "Open LDAP Public License v2.2",
343
+ "oldap-2.2.1": "Open LDAP Public License v2.2.1",
344
+ "oldap-2.2.2": "Open LDAP Public License 2.2.2",
345
+ "oldap-2.3": "Open LDAP Public License v2.3",
346
+ "oldap-2.4": "Open LDAP Public License v2.4",
347
+ "oldap-2.5": "Open LDAP Public License v2.5",
348
+ "oldap-2.6": "Open LDAP Public License v2.6",
349
+ "oldap-2.7": "Open LDAP Public License v2.7",
350
+ "oldap-2.8": "Open LDAP Public License v2.8",
351
+ "oml": "Open Market License",
352
+ "openssl": "OpenSSL License",
353
+ "opl-1.0": "Open Public License v1.0",
354
+ "oset-pl-2.1": "OSET Public License version 2.1",
355
+ "osl-1.0": "Open Software License 1.0",
356
+ "osl-1.1": "Open Software License 1.1",
357
+ "osl-2.0": "Open Software License 2.0",
358
+ "osl-2.1": "Open Software License 2.1",
359
+ "osl-3.0": "Open Software License 3.0",
360
+ "parity-6.0.0": "The Parity Public License 6.0.0",
361
+ "parity-7.0.0": "The Parity Public License 7.0.0",
362
+ "pddl-1.0": "ODC Public Domain Dedication & License 1.0",
363
+ "php-3.0": "PHP License v3.0",
364
+ "php-3.01": "PHP License v3.01",
365
+ "plexus": "Plexus Classworlds License",
366
+ "polyform-noncommercial-1.0.0": "PolyForm Noncommercial License 1.0.0",
367
+ "polyform-small-business-1.0.0": "PolyForm Small Business License 1.0.0",
368
+ "postgresql": "PostgreSQL License",
369
+ "psf-2.0": "Python Software Foundation License 2.0",
370
+ "psfrag": "psfrag License",
371
+ "psutils": "psutils License",
372
+ "python-2.0": "Python License 2.0",
373
+ "qhull": "Qhull License",
374
+ "qpl-1.0": "Q Public License 1.0",
375
+ "rdisc": "Rdisc License",
376
+ "rhecos-1.1": "Red Hat eCos Public License v1.1",
377
+ "rpl-1.1": "Reciprocal Public License 1.1",
378
+ "rpl-1.5": "Reciprocal Public License 1.5",
379
+ "rpsl-1.0": "RealNetworks Public Source License v1.0",
380
+ "rsa-md": "RSA Message-Digest License",
381
+ "rscpl": "Ricoh Source Code Public License",
382
+ "ruby": "Ruby License",
383
+ "sax-pd": "Sax Public Domain Notice",
384
+ "saxpath": "Saxpath License",
385
+ "scea": "SCEA Shared Source License",
386
+ "sendmail": "Sendmail License",
387
+ "sendmail-8.23": "Sendmail License 8.23",
388
+ "sgi-b-1.0": "SGI Free Software License B v1.0",
389
+ "sgi-b-1.1": "SGI Free Software License B v1.1",
390
+ "sgi-b-2.0": "SGI Free Software License B v2.0",
391
+ "shl-0.5": "Solderpad Hardware License v0.5",
392
+ "shl-0.51": "Solderpad Hardware License, Version 0.51",
393
+ "simpl-2.0": "Simple Public License 2.0",
394
+ "sissl": "Sun Industry Standards Source License v1.1",
395
+ "sissl-1.2": "Sun Industry Standards Source License v1.2",
396
+ "sleepycat": "Sleepycat License",
397
+ "smlnj": "Standard ML of New Jersey License",
398
+ "smppl": "Secure Messaging Protocol Public License",
399
+ "snia": "SNIA Public License 1.1",
400
+ "spencer-86": "Spencer License 86",
401
+ "spencer-94": "Spencer License 94",
402
+ "spencer-99": "Spencer License 99",
403
+ "spl-1.0": "Sun Public License v1.0",
404
+ "ssh-openssh": "SSH OpenSSH license",
405
+ "ssh-short": "SSH short notice",
406
+ "sspl-1.0": "Server Side Public License, v 1",
407
+ "standardml-nj": "Standard ML of New Jersey License",
408
+ "sugarcrm-1.1.3": "SugarCRM Public License v1.1.3",
409
+ "swl": "Scheme Widget Library (SWL) Software License Agreement",
410
+ "tapr-ohl-1.0": "TAPR Open Hardware License v1.0",
411
+ "tcl": "TCL/TK License",
412
+ "tcp-wrappers": "TCP Wrappers License",
413
+ "tmate": "TMate Open Source License",
414
+ "torque-1.1": "TORQUE v2.5+ Software License v1.1",
415
+ "tosl": "Trusster Open Source License",
416
+ "tu-berlin-1.0": "Technische Universitaet Berlin License 1.0",
417
+ "tu-berlin-2.0": "Technische Universitaet Berlin License 2.0",
418
+ "ucl-1.0": "Upstream Compatibility License v1.0",
419
+ "unicode-dfs-2015": "Unicode License Agreement - Data Files and Software (2015)",
420
+ "unicode-dfs-2016": "Unicode License Agreement - Data Files and Software (2016)",
421
+ "unicode-tou": "Unicode Terms of Use",
422
+ "unlicense": "The Unlicense",
423
+ "upl-1.0": "Universal Permissive License v1.0",
424
+ "vim": "Vim License",
425
+ "vostrom": "VOSTROM Public License for Open Source",
426
+ "vsl-1.0": "Vovida Software License v1.0",
427
+ "w3c": "W3C Software Notice and License (2002-12-31)",
428
+ "w3c-19980720": "W3C Software Notice and License (1998-07-20)",
429
+ "w3c-20150513": "W3C Software Notice and Document License (2015-05-13)",
430
+ "watcom-1.0": "Sybase Open Watcom Public License 1.0",
431
+ "wsuipa": "Wsuipa License",
432
+ "wtfpl": "Do What The F*ck You Want To Public License",
433
+ "wxwindows": "wxWindows Library License",
434
+ "x11": "X11 License",
435
+ "xerox": "Xerox License",
436
+ "xfree86-1.1": "XFree86 License 1.1",
437
+ "xinetd": "xinetd License",
438
+ "xnet": "X.Net License",
439
+ "xpp": "XPP License",
440
+ "xskat": "XSkat License",
441
+ "ypl-1.0": "Yahoo! Public License v1.0",
442
+ "ypl-1.1": "Yahoo! Public License v1.1",
443
+ "zed": "Zed License",
444
+ "zend-2.0": "Zend License v2.0",
445
+ "zimbra-1.3": "Zimbra Public License v1.3",
446
+ "zimbra-1.4": "Zimbra Public License v1.4",
447
+ "zlib": "zlib License",
448
+ "zlib-acknowledgement": "zlib/libpng License with Acknowledgement",
449
+ "zpl-1.1": "Zope Public License 1.1",
450
+ "zpl-2.0": "Zope Public License 2.0",
451
+ "zpl-2.1": "Zope Public License 2.1"
452
+ }
licenses.py ADDED
@@ -0,0 +1,327 @@
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
+ """
2
+ License objects.
3
+ """
4
+
5
+ import json
6
+ from dataclasses import dataclass
7
+ from types import SimpleNamespace
8
+ from typing import Dict, Optional
9
+
10
+
11
+ @dataclass
12
+ class License:
13
+ """
14
+ Base class from which all licenses inherit
15
+
16
+ Args:
17
+ name: License title
18
+ text: Accompanying information of the license
19
+ link: URL to License
20
+ version: Current version of license
21
+ provenance: Organization providing authorization, if possible
22
+ """
23
+
24
+ name: Optional[str] = None
25
+ short_name: Optional[str] = None
26
+ text: Optional[str] = None
27
+ link: Optional[str] = None
28
+ version: Optional[str] = None
29
+ provenance: Optional[str] = None
30
+
31
+ @property
32
+ def is_share_alike(self):
33
+ """
34
+ Is Share-alike?
35
+ """
36
+ # NOTE: leave here has an example of license properties
37
+ raise NotImplementedError()
38
+
39
+
40
+ @dataclass
41
+ class CustomLicense(License):
42
+ """
43
+ This class is for custom licenses.
44
+ It must contain the text of the license.
45
+ Optionally its version and a link to the license webpage.
46
+ """
47
+
48
+ def __post_init__(self):
49
+ if self.name is None:
50
+ self.name = "Custom license"
51
+
52
+ if self.text is None and self.link is None:
53
+ raise ValueError(
54
+ "A `CustomLicense` must provide either (a) the license text or (b) the license link!"
55
+ )
56
+
57
+
58
+ def _get_variable_name(k: str) -> str:
59
+
60
+ return k.replace("-", "_").upper().replace(".", "p").replace("+", "plus")
61
+
62
+
63
+ _GENIA_PROJECT_LICENSE_TEXT = """
64
+ GENIA Project License for Annotated Corpora
65
+
66
+ 1. Copyright of abstracts
67
+
68
+ Any abstracts contained in this corpus are from PubMed(R), a database
69
+ of the U.S. National Library of Medicine (NLM).
70
+
71
+ NLM data are produced by a U.S. Government agency and include works of
72
+ the United States Government that are not protected by U.S. copyright
73
+ law but may be protected by non-US copyright law, as well as abstracts
74
+ originating from publications that may be protected by U.S. copyright
75
+ law.
76
+
77
+ NLM assumes no responsibility or liability associated with use of
78
+ copyrighted material, including transmitting, reproducing,
79
+ redistributing, or making commercial use of the data. NLM does not
80
+ provide legal advice regarding copyright, fair use, or other aspects
81
+ of intellectual property rights. Persons contemplating any type of
82
+ transmission or reproduction of copyrighted material such as abstracts
83
+ are advised to consult legal counsel.
84
+
85
+ 2. Copyright of full texts
86
+
87
+ Any full texts contained in this corpus are from the PMC Open Access
88
+ Subset of PubMed Central (PMC), the U.S. National Institutes of Health
89
+ (NIH) free digital archive of biomedical and life sciences journal
90
+ literature.
91
+
92
+ Articles in the PMC Open Access Subset are protected by copyright, but
93
+ are made available under a Creative Commons or similar license that
94
+ generally allows more liberal redistribution and reuse than a
95
+ traditional copyrighted work. Please refer to the license of each
96
+ article for specific license terms.
97
+
98
+ 3. Copyright of annotations
99
+
100
+ The copyrights of annotations created in the GENIA Project of Tsujii
101
+ Laboratory, University of Tokyo, belong in their entirety to the GENIA
102
+ Project.
103
+
104
+ 4. Licence terms
105
+
106
+ Use and distribution of abstracts drawn from PubMed is subject to the
107
+ PubMed(R) license terms as stated in Clause 1.
108
+
109
+ Use and distribution of full texts is subject to the license terms
110
+ applying to each publication.
111
+
112
+ Annotations created by the GENIA Project are licensed under the
113
+ Creative Commons Attribution 3.0 Unported License. To view a copy of
114
+ this license, visit http://creativecommons.org/licenses/by/3.0/ or
115
+ send a letter to Creative Commons, 444 Castro Street, Suite 900,
116
+ Mountain View, California, 94041, USA.
117
+
118
+ Annotations created by the GENIA Project must be attributed as
119
+ detailed in Clause 5.
120
+
121
+ 5. Attribution
122
+
123
+ The GENIA Project was founded and led by prof. Jun'ichi Tsujii and
124
+ the project and its annotation efforts have been coordinated in part
125
+ by Nigel Collier, Yuka Tateisi, Sang-Zoo Lee, Tomoko Ohta, Jin-Dong
126
+ Kim, and Sampo Pyysalo.
127
+
128
+ For a complete list of the GENIA Project members and contributors,
129
+ please refer to http://www.geniaproject.org.
130
+
131
+ The GENIA Project has been supported by Grant-in-Aid for Scientific
132
+ Research on Priority Area "Genome Information Science" (MEXT, Japan),
133
+ Grant-in-Aid for Scientific Research on Priority Area "Systems
134
+ Genomics" (MEXT, Japan), Core Research for Evolutional Science &
135
+ Technology (CREST) "Information Mobility Project" (JST, Japan),
136
+ Solution Oriented Research for Science and Technology (SORST) (JST,
137
+ Japan), Genome Network Project (MEXT, Japan) and Grant-in-Aid for
138
+ Specially Promoted Research (MEXT, Japan).
139
+
140
+ Annotations covered by this license must be attributed as follows:
141
+
142
+ Corpus annotations (c) GENIA Project
143
+
144
+ Distributions including annotations covered by this licence must
145
+ include this license text and Attribution section.
146
+
147
+ 6. References
148
+
149
+ - GENIA Project : http://www.geniaproject.org
150
+ - PubMed : http://www.pubmed.gov/
151
+ - NLM (United States National Library of Medicine) : http://www.nlm.nih.gov/
152
+ - MEXT (Ministry of Education, Culture, Sports, Science and Technology) : http://www.mext.go.jp/
153
+ - JST (Japan Science and Technology Agency) : http://www.jst.go.jp
154
+ """
155
+
156
+ GeniaProjectLicense = CustomLicense(
157
+ name="GENIA Project License for Annotated Corpora",
158
+ # NOTE: just in case the link will break
159
+ text=_GENIA_PROJECT_LICENSE_TEXT,
160
+ link="http://www.nactem.ac.uk/meta-knowledge/GENIA_license.txt",
161
+ )
162
+
163
+
164
+ _NLM_LICENSE_TEXT = """
165
+ National Library of Medicine Terms and Conditions
166
+
167
+ INTRODUCTION
168
+
169
+ Downloading data from the National Library of Medicine FTP servers indicates your acceptance of the following Terms and Conditions: No charges, usage fees or royalties are paid to NLM for this data.
170
+
171
+ GENERAL TERMS AND CONDITIONS
172
+
173
+ Users of the data agree to:
174
+ acknowledge NLM as the source of the data by including the phrase "Courtesy of the U.S. National Library of Medicine" in a clear and conspicuous manner,
175
+ properly use registration and/or trademark symbols when referring to NLM products, and
176
+ not indicate or imply that NLM has endorsed its products/services/applications.
177
+
178
+ Users who republish or redistribute the data (services, products or raw data) agree to:
179
+ maintain the most current version of all distributed data, or
180
+ make known in a clear and conspicuous manner that the products/services/applications do not reflect the most current/accurate data available from NLM.
181
+
182
+ These data are produced with a reasonable standard of care, but NLM makes no warranties express or implied, including no warranty of merchantability or fitness for particular purpose, regarding the accuracy or completeness of the data. Users agree to hold NLM and the U.S. Government harmless from any liability resulting from errors in the data. NLM disclaims any liability for any consequences due to use, misuse, or interpretation of information contained or not contained in the data.
183
+
184
+ NLM does not provide legal advice regarding copyright, fair use, or other aspects of intellectual property rights. See the NLM Copyright page.
185
+
186
+ NLM reserves the right to change the type and format of its machine-readable data. NLM will take reasonable steps to inform users of any changes to the format of the data before the data are distributed via the announcement section or subscription to email and RSS updates.
187
+
188
+ """
189
+ NLMLicense = CustomLicense(
190
+ name="National Library of Medicine Terms and Conditions",
191
+ # NOTE: just in case the link will break
192
+ text=_NLM_LICENSE_TEXT,
193
+ link="https://www.nlm.nih.gov/databases/download/terms_and_conditions.html",
194
+ )
195
+
196
+
197
+ _PHYSIONET_LICENSE_1p5_TEXT = """
198
+ The PhysioNet Credentialed Health Data License
199
+ Version 1.5.0
200
+
201
+ Copyright (c) 2022 MIT Laboratory for Computational Physiology
202
+
203
+ The MIT Laboratory for Computational Physiology (MIT-LCP) wishes to make data available for research and educational purposes to qualified requestors, but only if the data are used and protected in accordance with the terms and conditions stated in this License.
204
+
205
+ It is hereby agreed between the data requestor, hereinafter referred to as the "LICENSEE", and MIT-LCP, that:
206
+
207
+ The LICENSEE will not attempt to identify any individual or institution referenced in PhysioNet restricted data.
208
+ The LICENSEE will exercise all reasonable and prudent care to avoid disclosure of the identity of any individual or institution referenced in PhysioNet restricted data in any publication or other communication.
209
+ The LICENSEE will not share access to PhysioNet restricted data with anyone else.
210
+ The LICENSEE will exercise all reasonable and prudent care to maintain the physical and electronic security of PhysioNet restricted data.
211
+ If the LICENSEE finds information within PhysioNet restricted data that he or she believes might permit identification of any individual or institution, the LICENSEE will report the location of this information promptly by email to PHI-report@physionet.org, citing the location of the specific information in question.
212
+ The LICENSEE will use the data for the sole purpose of lawful use in scientific research and no other.
213
+ The LICENSEE will be responsible for ensuring that he or she maintains up to date certification in human research subject protection and HIPAA regulations.
214
+ The LICENSEE agrees to contribute code associated with publications arising from this data to a repository that is open to the research community.
215
+ This agreement may be terminated by either party at any time, but the LICENSEE's obligations with respect to PhysioNet data shall continue after termination.
216
+
217
+ THE DATA ARE PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM, OUT OF OR IN CONNECTION WITH THE DATA OR THE USE OR OTHER DEALINGS IN THE DATA.
218
+ """
219
+ PhysioNetLicense1p5 = CustomLicense(
220
+ name="PhysioNet Credentialed Health Data License",
221
+ version="1.5",
222
+ link="https://physionet.org/content/mimiciv/view-license/0.4/",
223
+ # NOTE: just in case the link will break
224
+ text=_PHYSIONET_LICENSE_1p5_TEXT,
225
+ )
226
+
227
+
228
+ UMLSLicense = CustomLicense(
229
+ name="UMLS - Metathesaurus License Agreement",
230
+ link="https://www.nlm.nih.gov/research/umls/knowledge_sources/metathesaurus/release/license_agreement.html",
231
+ )
232
+
233
+ _NCBI_LICENSE_TEXT = """
234
+ ===========================================================================
235
+ *
236
+ * PUBLIC DOMAIN NOTICE
237
+ * National Center for Biotechnology Information
238
+ *
239
+ * This software/database is a "United States Government Work" under the
240
+ * terms of the United States Copyright Act. It was written as part of
241
+ * the author's official duties as a United States Government employee and
242
+ * thus cannot be copyrighted. This software/database is freely available
243
+ * to the public for use. The National Library of Medicine and the U.S.
244
+ * Government have not placed any restriction on its use or reproduction.
245
+ *
246
+ * Although all reasonable efforts have been taken to ensure the accuracy
247
+ * and reliability of the software and data, the NLM and the U.S.
248
+ * Government do not and cannot warrant the performance or results that
249
+ * may be obtained by using this software or data. The NLM and the U.S.
250
+ * Government disclaim all warranties, express or implied, including
251
+ * warranties of performance, merchantability or fitness for any particular
252
+ * purpose.
253
+ *
254
+ * Please cite the author in any work or product based on this material.
255
+ *
256
+ *
257
+ ===========================================================================
258
+ """
259
+ NCBILicense = CustomLicense(
260
+ name="National Center fr Biotechnology Information PUBLIC DOMAIN NOTICE",
261
+ link="https://github.com/openbiocorpora/genetag/blob/master/LICENSE",
262
+ # NOTE: just in case link will break
263
+ text=_NCBI_LICENSE_TEXT,
264
+ )
265
+
266
+ PublicDomainMark_1p0 = CustomLicense(
267
+ name="Public Domain Mark 1.0",
268
+ text="""This work has been identified as being free of known restrictions under copyright law,
269
+ including all related and neighboring rights.
270
+ """,
271
+ link="https://creativecommons.org/publicdomain/mark/1.0/",
272
+ )
273
+
274
+
275
+ def load_json_licenses() -> Dict[str, str]:
276
+ """
277
+ Load all licenses from JSON file.
278
+ Amend names to be valid variable names
279
+ """
280
+
281
+ # shamelessly compied from:
282
+ # https://github.com/huggingface/datasets/blob/master/src/datasets/utils/metadata.py
283
+ licenses = {
284
+ _get_variable_name(k): v
285
+ for k, v in json.loads(
286
+ open("licenses.json", "r").read()
287
+ ).items()
288
+ }
289
+
290
+ licenses["ZERO_BSD"] = licenses.pop("0BSD")
291
+
292
+ return licenses
293
+
294
+
295
+ def load_licenses() -> Dict[str, License]:
296
+ """
297
+ Load `_LICENSES` dict:
298
+ - key (str) : license name
299
+ - value (License) : instance of license class
300
+ """
301
+
302
+ json_licenses = load_json_licenses()
303
+
304
+ json_licenses.update({"DUA": "Data User Agreement"})
305
+
306
+ licenses_kwargs = {k: {"name": v} for k, v in json_licenses.items()}
307
+
308
+ licenses = {k: License(**kwargs) for k, kwargs in licenses_kwargs.items()}
309
+
310
+ custom_licenses = {
311
+ "PUBLIC_DOMAIN_MARK_1p0": PublicDomainMark_1p0,
312
+ "GENIA_PROJECT_LICENSE": GeniaProjectLicense,
313
+ "NLM_LICENSE": NLMLicense,
314
+ "NCBI_LICENSE": NCBILicense,
315
+ "UMLS_LICENSE": UMLSLicense,
316
+ "PHYSIONET_LICENSE_1p5": PhysioNetLicense1p5,
317
+ }
318
+
319
+ licenses.update(custom_licenses)
320
+ for k, v in licenses.items():
321
+ v.short_name = k
322
+
323
+ return licenses
324
+
325
+
326
+ _LICENSES = load_licenses()
327
+ Licenses = SimpleNamespace(**_LICENSES)